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 Alzheimer’s  disease (AD) is the most common form of dementia and completely 
lacks any viable, long-term therapeutic intervention. This is partly due to an incomplete 
understanding of AD etiology and the possible confounding factors associated with its 
genotypic and phenotypic heterogeneity. Cerebral amyloid angiopathy (CAA) is a 
common, yet frequently overlooked, pathology associated with AD. A pathological 
hallmark of AD consists of extracellular amyloid-beta  (Aβ)  deposits,  while  CAA  
manifests  with  deposition  Aβ  within  the  smooth  muscle  layer of cerebral arteries and 
arterioles. The role of  Aβ  in  AD  and  CAA  pathophysiology  has  long  been  controversial. 
Although it may have toxic effects at super-physiological  levels,  Aβ  load  does  not  
necessarily correlate with cognitive demise in humans. Described in this dissertation is an 
alternative  viewpoint  that  the  toxicity  afforded  by  Aβ  could be due, in part, to 
complement system activation—a potent inflammatory cascade, which left unchecked 
can cause robust cell death. We have found increased levels of the lytic Membrane 
Attack Complex (MAC) on vessels harboring CAA compared to vessels from AD 
patients without CAA and pathological controls. Additionally, the same vessels also 
show trending decreases in the endogenous MAC inhibitor, CD59. We believe the 
 xii 
differential complement phenotype on vessels could be due to an upstream shift in how 
Aβ  is  trafficked  to  the  blood  stream  for  clearance.  We  found  more  Aβ  bound  to the 
microglial CD11b receptor through complement C3b in CAA patients compared to AD 
and control subjects. Additionally, 75% of CAA patients in this cohort harbor the CAA 
risk haplotype rs6656401 at the CR1 gene, which seems to modify the localization of 
CR1 molecules from the membrane to endosomal structures. Because CR1 functions on 
the cell surface to block C3b generation, mislocalization to intracellular compartments 
may explain the increased C3b found in subjects with CAA. Increased availability of 
parenchymal  C3b  to  bind  Aβ  may  explain  the  robust  staining  of  MAC  on  CAA  blood  
vessels. These observations in human postmortem brain help explain the high frequency 
of microbleeds and hemorrhage associated with CAA and may offer a novel therapeutic 
target to reduce these life-threatening events. 
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CHAPTER ONE 
INTRODUCTION 
 
 
Epidemiology and Genetics of Alzheimer’s  Disease   
Alzheimer’s  disease  (AD)  is  the  most common form of clinical dementia. 
According  to  the  Alzheimer’s  Association’s  2012  facts  and  figures  data  sheet,  it  is  the  
sixth leading cause of death and has a prevalence of one in eight in the United States with 
an expected incidence up to 16 million by 2050 (Alzheimer's 2012). A separate, even 
more sobering statistic for the AD field is the decrease in the number of deaths in other 
high morbidity diseases such as HIV (-29%), stroke (-20%), heart disease (-13%) and 
breast (-3%) and prostate cancer (-8%), but a 66% increase in the number of deaths from 
AD between 2000 and 2008 (Alzheimer's 2012). Researchers have postulated that an 
increase in the ageing population has led to the immense burden of AD prevalence. This 
is based on the exponentially increased incidence of AD as age increases, so that by age 
85, incidence rates in North America reach above 6.0% (Mayeux and Stern 2012), while 
annual regional incidence is above 10% in North America (Ferri, Prince et al. 2005).  
Other environmental risk factors, such as traumatic brain injury, smoking, diet and 
exercise and their effects on cardiovascular (including cerebrovascular) disease, 
hypertension, and type II diabetes seem to play a role in AD epidemiology and these are 
thoroughly reviewed by Mayeux and Stern (2012) and by Reitz et al. (Reitz, Brayne et al. 
2011). These staggering increases in AD prevalence and progression are important to 
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understand in the light of their impending burden on healthcare and the new laws set to 
take place in 2014 as a part of the Affordable Care Act.  
 The very first case to be described by Alois Alzheimer, which debuted the classic 
“plaques  and  tangles”  view of pathology and clinical memory loss, was officially 
classified later as an early onset form of AD (Lage 2006). The autosomal dominant 
mutations in the amyloid precursor protein (APP) gene and an enzyme involved in its 
metabolism,  the  presenilin  component  of  γ-secratase (PSEN1 and PSEN2), are thought to 
cause familial AD. These rare mutations result in an overproduction of the amyloid-β  
(Aβ)  peptide,  which  is  hypothesized  to  be  toxic  to neurons at high levels. The sporadic, 
late onset form, however, seems to be much more complicated, with no apparent 
overproduction  of  Aβ,  but  similar  pathology.   
With the overwhelming majority (>95%) of AD cases manifesting as sporadic, 
late onset cognitive decline, the startling statistics presented in the previous section have 
ushered in an intense push for understanding the pathophysiological mechanisms of AD 
at the genetic and molecular level. With the new age of human genomics upon us and the 
recent advent of genome-wide association studies (GWAS), we have a much more 
complex understanding of the genetic influences on AD and other neurodegenerative 
diseases. In 2007, it was confirmed by a GWA study that APOE4 was the most important 
risk gene for late onset AD (Coon, Myers et al. 2007). Unfortunately, the field of AD has 
still failed to agree on how the  ε4  allele  of  ApoE  effects  the  AD  phenotype,  although  
several hypotheses have been described. The ApoE protein plays a role in cholesterol 
(Mahley 1988) and amyloid-β  trafficking  (Strittmatter, Weisgraber et al. 1993), and 
functions as an anti-inflammatory agent (Guo, LaDu et al. 2004). In each of these cases, 
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the  ε4  allotype  functions  less  efficiently  than  its  neutral  ε3  and  protective  ε2  counterparts.  
Recently, common variants with intermediate penetrance from whole-exome sequencing 
have been implicated in increased AD risk (Bertram and Tanzi 2008, Harold, Abraham et 
al. 2009, Lambert, Heath et al. 2009, Guerreiro, Wojtas et al. 2012, Jonsson, Stefansson 
et al. 2012). The diversity of proteins and their functions encoded by these genetic risk 
variants highlights the complexity of AD pathogenesis, many of which represent classes 
of proteins involved in inflammation, cholesterol homeostasis and endocytosis and 
intracellular trafficking. The evidence of multiple genetic risk factors suggests a 
paradigm of multiple disease etiologies and may bring more relevance to the notion of 
personalized medicine. 
 
Pathological and Clinical Diagnosis of AD 
 Alzheimer’s  disease  is  considered  a  dual  clinicopathologic  entity  consisting  of  a  
clinical phenotype of episodic memory impairment along with involvement of some other 
cognitive domain or skill. The pathologic diagnosis of AD, which is usually only 
ascertained  at  autopsy,  centers  around  the  presence  of  extracellular  plaques  of  Aβ42  and  
intracellular neurofibrillary tangles of the microtubule associated protein tau (MAPT). 
Many cases of AD, however, frequently involve other clinical and pathological variants. 
Mixed dementia with other neurodegenerative disease symptoms and pathology 
comprising AD variants and subtypes, such as vascular dementia (Selnes and Vinters 
2006), frontotemporal lobar degeneration (Johnson, Head et al. 1999), posterior cortical 
atrophy (Crutch, Lehmann et al. 2012), Lewy body disease (Duyckaerts, Delatour et al. 
2009), hippocampal sclerosis (Nelson, Head et al. 2011) and Tar DNA binding protein-43 
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(TDP-43) (Wilson, Dugger et al. 2011) are common and may confound the diagnosis of 
AD, which may explain the failures of some AD clinical trials. Because of the 
heterogeneity of clinical and pathologic findings, the diagnosis of AD can only be made 
in  terms  of  “probable”  or  “possible”  AD.  So, necessarily, in persons manifesting 
clinically with dementia, pathological evidence of plaques and tangles is required for a 
diagnosis of AD, while a postmortem diagnosis of AD can only be inferred with 
subsequent clinical dementia in the living patient (Hyman and Trojanowski 1997).  
 Several classification schemes have been presented over the years by different 
workgroups charged with developing clinical and pathological criteria for AD diagnosis. 
The first was published in 1984 by the National Institute of Neurological and 
Communicative  Disorders  and  Stroke  (NINCDS)  and  the  Alzheimer’s  disease  and  
Related Disorders Association (ADRDA), which would establish the clinical criteria for 
AD diagnosis based on medical history, laboratory values, neuropsychological testing 
and clinical examination (McKhann, Drachman et al. 1984). 25 years later, these 
guidelines have now been updated to include advances in imaging modalities, our 
understanding of the genetic and pathophysiological basis of AD, improvements in 
clinically discriminating AD from other neurodegenerative diseases, recognition of 
preclinical and Mild Cognitive Impairment (MCI) stages and a need for feasible 
molecular markers predictive of disease onset (Albert, DeKosky et al. 2011, Jack, Albert 
et al. 2011, McKhann, Knopman et al. 2011, Sperling, Aisen et al. 2011). The updated 
criteria  established  by  the  National  Institute  on  Aging  (NIA)  and  the  Alzheimer’s  
Association (AA) workgroup are not the first suggestions attempting to advance the field 
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(Dubois, Feldman et al. 2007, Dubois, Feldman et al. 2010), however they are the first 
since the NINCDS-ADRDA to have a large consensus from the AD community.  
 
Summary of AD Pathological Hallmarks 
 Although Alois Alzheimer himself first described the pathological hallmarks of 
AD over 100 years ago, they remain to this day the only standardized confirmatory 
evidence of AD. The first of the two abnormal deposits to be identified was the 
constituent of the miliary foci described by Alzheimer, which would later be called senile 
plaques. In 1984, Glenner and Wong identified  and  sequenced  the  4  kDa  Aβ  peptide,  
which they isolated from leptomeningeal blood vessels of AD patients (Glenner and 
Wong 1984). The same peptide was then identified in partially purified parenchymal 
plaques a year later (Masters, Simms et al. 1985).  Aβ  has  two  allotypes  of  slightly  
different length; a 42 amino acid form, which is normally found at a higher ratio in the 
parenchyma compared to the 40 amino acid form, which makes up a greater proportion of 
vascular lesions. Sequential enzymatic cleavage of the parent amyloid precursor protein 
(APP) generates both peptides. The 39-43  residue  Aβ  sequence  is  positioned  28  residues  
amino-terminal from the trans-membrane domain and extends 11-15 residues into the 
hydrophobic plasma membrane (Kang, Lemaire et al. 1987).  
β-secretase  (β-site APP-cleaving enzyme 1; BACE1) initiates cleavage at the APP 
site  28  residues  from  the  membrane,  releasing  the  extracellular  domain  (sAPPβ)  and  
retaining the carboxy-terminal 99 residues (C99) (Vassar, Bennett et al. 1999) (Figure 1). 
C99  is  a  substrate  for  the  intramembranous  γ-secretase, which contains four protease 
components of which two are presenilin  1  and  2,  generating  Aβ  and  the  APP  intracellular  
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domain (AICD) (Gandy 2005). Generation of the hydrophobic and thus more 
fibrillogenic  Aβ42  begins  as  soluble  monomers,  but  conformational  changes  result  in  
formation  of  β-pleated sheet deposits. It is thought that the extra two amino acid residues 
on the carboxy-terminus  of  Aβ42  precipitate the nucleation of parenchymal amyloid 
plaques (Jarrett, Berger et al. 1993).  The  aggregation  of  Aβ  into  insoluble  plaques  and  its  
equilibrium  with  intermediate  soluble  Aβ  oligomers  is  thought  to  cause  synaptic  
dysfunction and altered neuronal ionic homeostasis (Palop and Mucke 2010, Benilova, 
Karran et al. 2012).  The  theory  of  Aβ  oligomer-mediated synaptic deficits should be 
taken  with  caution,  however,  owing  to  the  lack  of  evidence  of  such  Aβ  species  in  the  
living human brain. These insults then result in abnormal kinase/phosphatase activity, 
which then lead to the hyperphosphorylation of MAPT and the second hallmark 
pathology of AD, neurofibrillary tangles (NFT). This cascade has been described as the 
Amyloid Cascade Hypothesis (Hardy and Higgins 1992). Recently, the amyloid cascade 
hypothesis has come under scrutiny and although it may have merit in downstream 
pathogenesis, amyloid aggregation does not seem to be the initial cause of AD, but 
possibly an adaptive response to some other insult (Robinson and Bishop 2002, Lee, 
Casadesus et al. 2004, Herrup 2010, Marchesi 2011, Castello and Soriano 2012). 
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Figure 1. Diagram depicting processing of the amyloid precursor protein along the 
amyloidogenic pathway and  its  consequences  in  terms  of  Aβ  aggregation. 
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The  second  half  of  the  amyloid  cascade,  thought  to  be  dependent  on  Aβ,  is  the  
hyperphosphorylation of MAPT, forming paired helical filaments (PHF), which are the 
main constituents of intracellular NFTs. Tau normally binds to microtubules in healthy 
neurons through its four microtubule binding domains and contributes to microtubule 
assembly and stability. Immunological studies determined abnormally phosphorylated tau 
as the main component of PHFs (Grundke-Iqbal, Iqbal et al. 1986, Nukina and Ihara 
1986), however tau was not cloned and sequenced until 1988, thus proving tangles were 
composed of hyperphosphorylated tau (Goedert, Wischik et al. 1988). Tau 
phosphorylation is regulated by several kinases and phosphatases (eg, GSK-3β  and  PPA-
1, respectively) (Iqbal, Alonso Adel et al. 2005). The evidence of tau pathology is 
accompanied by synapse regression and neuronal death, which directly results in 
neurodegenerative manifestation (Terry, Masliah et al. 1991). Braak staging is a verified 
method of classifying the extent of AD progression at autopsy via NFT distribution 
throughout the neocortex (Braak and Braak 1991). 
 
Clinical Diagnosis: The Need for Early Biomarkers 
 AD is a slowly progressing form of dementia, not unlike other forms of cognitive 
decline. Naturally, diagnostic accuracy of 100% as the gold standard is desirable for any 
disorder in order to apply effective therapies. A recent analysis of the current accuracy of 
clinical and pathological diagnostics for AD ranged from 70.9% to 87.3% sensitive and 
44.3% to 70.8% specific (Beach, Monsell et al. 2012). Additionally, the positive 
predictive value (PPV), which defines the precision rate of true positives, was 83%. This 
study gathered data from the National Institute on Ageing (NIA)-sponsored  Alzheimer’s  
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Disease Centers (ADC), yielding the conclusion that the accuracy rate of clinical 
diagnosis of AD varied with the clinical and pathological criteria used. Because most 
studies only present the sensitivity or the PPV (which are normally higher than the 
specificity), the field of AD has gathered the impression that the AD diagnosis is 
exceptionally accurate. 
 The notion of increasing the diagnostic accuracy of AD at earlier time points has 
been sought for some time. New diagnostic criteria for detecting AD earlier in its 
preclinical stages heavily emphasizes the use of image- and fluid-based biomarkers 
(Sperling, Aisen et al. 2011). A recent model describing longitudinal changes in five of 
the most established biomarkers has been proposed in relation to AD progression (Jack, 
Knopman et al. 2013).  The  authors  propose  a  temporally  ordered  alteration  in  CSF  Aβ  
levels,  Aβ  PiB  retention  on  positron  emission  tomography  (PET)  imaging,  CSF  tau  
levels, structural magnetic resonance imaging (MRI) and 18F-deoxyglucose PET, which 
all precede clinical symptoms of cognitive impairment. The longitudinal aspect of these 
markers is quite important as it allows for a view of the temporal dynamics of each 
marker that can possibly predict onset and outcome of the disease, but they are not yet 
ready for clinical use for two reasons: 1) the imaging modalities described are very 
expensive for routine, repeated use in prospective AD patients and use of radioactive PET 
tracers can be systemically dangerous over time; 2) although soluble analytes in CSF 
would be very valuable as they are directly related to the brain milieu, repeated painful 
lumber punctures in elderly patients would not be feasible. We propose, as many others 
have, that the ideal soluble biomarker would come from peripheral blood as it is cheap to 
obtain, easy to perform by most medical professionals, much less time consuming and 
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less painful for the patient over repeated blood draws. This last point is important for 
implementation of prospective analysis of candidate markers.  
 Our lab has extensive experience in blood-based biomarker discovery (Magaki, 
Mueller et al. 2007, Mueller, Zhou et al. 2010) and have accumulated a wealth of data on 
serum proteins through LC-MS/MS proteomics in a prospective cohort of community 
dwelling subjects. Patients began the study in either the cognitively normal control group 
or the MCI group and were followed for several years. Patients progressing to dementia 
were then placed in the progressive MCI (AD) group and were further split into AD 
patients with and without susceptibility weighted MRI evidence of microbleeds, 
indicative of CAA.  
Because of our interest in inflammatory mechanisms and their overwhelming 
association with AD pathogenesis (Magaki, Mueller et al. 2007, Magaki, Yellon et al. 
2008), we chose to answer the question of whether complement activation products and 
other  acute  phase  response  proteins  associated  with  inflammation  and  clearance  of  Aβ  
were changed in the serum of our cohort. We also asked if these proteins could 
differentiate between AD patients with and without CAA. Although there were 
differences between groups in the cross-sectional portion of the study for Complement 
C3 and C4, C1-inhibitor and alpha-2-macroglobulin (a2M), these proteins failed to 
predict conversion from MCI to AD-only or AD/CAA in the longitudinal portion, nor 
were there significant differences (Zabel, Schrag et al. 2012). Interestingly, there was a 
trending increase in both a2M and C3 in the stable MCI patients early, which tapered off 
down to levels similar to those patients who did not progress, which could indicate these 
patients are earlier on in the disease process or have higher cognitive reserve. Although it 
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has been difficult to make conclusions from current findings in peripheral blood, more 
work should be done looking at separate blood fractions. For example, ongoing work in 
our lab is surveying the exosome fraction, specifically from myeloid cells, of serum in a 
longitudinal cohort. 
 
Introduction to Cerebral Amyloid Angiopathy 
Cerebral amyloid angiopathy (CAA) is a not so rare, yet frequently overlooked 
pathology of the cerebral blood vessels that can have detrimental effects on blood vessel 
architecture (i.e. aneurism formation, vessel fragmentation and double barreling; Figure 
2) and auto-regulatory function. The importance of CAA as a clinical and pathologic 
entity arises from its association with AD and aging and its contribution to non-traumatic, 
normotensive, lobar  hemorrhage.  The  molecular  and  cellular  pathomechanisms  of  Aβ  
deposition in the walls of cerebral blood vessels and the resulting weakening of those 
blood vessels have thus far remained an enigma.  
 
Detection and Diagnosis of CAA 
 Much like an AD diagnosis, confirmatory evidence of CAA can only be obtained 
at autopsy or by rare cortical biopsy. This, again, makes biomarker discovery important 
in order to apply appropriate and timely therapies, although there are no therapies at 
present, aside from the potential of anti-inflammatory response to steroids in a subset of 
patients manifesting inflammatory CAA (Harkness, Coles et al. 2004, Kloppenborg, 
Richard et al. 2010, Kimura, Sakurai et al. 2013). Identification of CAA patients has 
important clinical implications. There has been association of cerebral microbleeds and 
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frank hemorrhages after anticoagulant therapy in patients with CAA (Smith, Hitchcock et 
al. 1985, Vernooij, Haag et al. 2009, Biffi, Halpin et al. 2010). This makes sense in light 
of the understanding that CAA-affected blood vessels suffer from a so far undefined 
vasculotoxic insult rendering them fragile and easily ruptured. This and the fact that the 
BBB in CAA is already inherently leaky, anticoagulant therapy (i.e. aspirin, warfarin, 
etc.) would exacerbate the pathology. In addition, emerging data from our laboratory has 
indicated separate disease etiologies between AD without CAA and AD with CAA 
(Schrag, McAuley et al. 2010, Schrag, Crofton et al. 2011), warranting further 
differentiation and identification of these patients.  
 CAA can be clinically diagnosed using the Boston Criteria. Although definitive 
diagnose can only be obtained at autopsy, Knudsen et al. (2001) validated that with 
appropriate clinical and radiologic evidence, a reliable antemortem diagnosis was feasible 
(Knudsen, Rosand et al. 2001). Clinical information ascertained upon patient interview 
depends on the size and location of the hemorrhage, with large lobar hemorrhages 
manifesting as contralateral hemiparesis and depressed cognition and smaller 
microhemorrhages causing focal deficits, seizures or headache. Interestingly, the smaller 
microbleeds seem to cluster in posterior regions of the brain (Rosand, Muzikansky et al. 
2005) and are associated with Pittsburgh Compound B (PiB) retention on Positron 
Emission Tomography (PET) (Dierksen, Skehan et al. 2010),  indicative  of  Aβ  deposition.  
These clinical findings describe either probable CAA with supporting pathology, 
probable CAA, or possible CAA. The former is established only with availability of 
evacuated hematoma or a cortical biopsy and demonstrating the presence of congophilic 
staining without other diagnostic lesions (Greenberg and Vonsattel 1997). Probable and 
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possible CAA diagnoses are made on the grounds of clinical data (hemorrhage or 
microbleed cortical localization on patient interview) and gradient-echo MRI or CT 
evidence of multiple lobar hemorrhages or single lobar hemorrhage, respectively and 
both presenting  at  age  ≥55  years  and  absence  of  other  hemorrhage  etiology  (Knudsen, 
Rosand et al. 2001). Based on the limitations of current diagnostic methodologies, it will 
be important for future exploration of genetic and molecular markers that differentiate 
patients harboring vascular Aβ pathology.  
 
Aβ  Deposition:  Cerebral  Topology  and  Vessel  Distribution 
Characterized  by  deposition  of  Aβ  within  the  adventitia  and  media  of  
leptomeningeal arteries and cortical arterioles, CAA is a major contributor to vascular 
fragility and fatal hemorrhages and thus, cognitive decline. Affected vessels normally 
localize to posterior brain regions (occipital and parietal regions) (Tomonaga 1981, 
Vinters and Gilbert 1983, Pfeifer, White et al. 2002, Attems, Quass et al. 2007), with 
vessels of the occipital cortex most severely effected (Attems, Jellinger et al. 2005). 
Some authors, however, have reported the frontal cortex as the main site of CAA 
pathology (Masuda 1985, Xu, Yang et al. 2003).  This topographical distribution 
manifests functional impairments in the visual and visual association areas as evidenced 
during visually invoked tasks (Smith, Vijayappa et al. 2008).  
The  distribution  of  Aβ  deposition  follows  a  regionally  specific  path  of  vessels,  
although this distribution can be patchy and focal, in which adjacent histological  
sections can have a heterogeneous pattern of CAA-affected vessels. Most frequently, 
arteries of the leptomeninges show the earliest signs of pathology followed by penetrating 
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Figure 2. Cerebral amyloid angiopathy. A) typical morphology of severe CAA-affected 
artery. Notice the acellular tunica media and aneurysm formation. B-C) Isolated vessels 
from a moderate CAA case and stained with congo red dye for fibrillar amyloid. Note the 
banding   pattern,   which   has   been   suggested   to   represent   intercalation   of   Aβ   between  
vascular smooth muscle cells. D) Fluorescent staining of CAA-affected cortical arteries 
with thioflavin. E) Staining of leptomeningeal  and cortical penetrating arteries in a CAA 
case   for  Aβ  using   the  6E10  antibody.  F)  A  cortical   artery   showing  Aβ   staining   strictly  
within the vascular smooth muscle media layer using the M31 antibody, which is highly 
selective for vascular amyloid. Scale bars; A,E,F = 200   μm,   D   =   400   μm
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arterioles in the neocortical grey matter (Preston, Steart et al. 2003). A second stage 
consists of pathology in the allocortical areas and cerebellum, followed by a third stage, 
which is characterized by involvement of deep grey matter and white matter (Mann, 
Pickering-Brown et al. 2001, Thal, Ghebremedhin et al. 2003). 
Within  the  vessel  wall  itself,  Aβ  deposition  can  also  be  classified  into  three  stages  
based on severity as described by Vonsattel (Vonsattel, Myers et al. 1991). Deposition 
begins on  the  abluminal  surface  of  affected  vessels  with  restriction  of  Aβ  as  a  rim  around  
smooth muscle cells (SMCs) in the adventitia and media classified as mild CAA; 
moderate  CAA  is  defined  by  the  replacement  of  SMCs  by  Aβ  and  thickening  of  the  
media without blood  extravasation;;  severe  CAA  denotes  extensive  Aβ  deposition  with  
break down of the vessel wall and perivascular leakage (Vonsattel, Myers et al. 1991). 
Although this method is qualitative and only measures parameters associated with one 
vessel, the new guidelines set by the NIA-AA workgroup for neuropathologic assessment 
of AD suggest surveying multiple regions for these phases of CAA (Montine, Phelps et 
al. 2012).  
 The above description of CAA pathology represents CAA type 2, in which only 
vessels containing the SMC medial layer develop amyloidosis. A second type, CAA type 
1, involves both vessels with SMCs and those that do not—mainly capillaries and is more 
frequently associated with parenchymal AD pathology (Thal, Ghebremedhin et al. 2002). 
CAA  of  capillaries  is  aptly  named  capCAA.  Deposition  of  Aβ  in  CAA  type  1  takes  on  a  
peculiar plaque-like distribution at the capillary basement membrane extending out into 
the surrounding neuropil or simply builds up along the abluminal capillary wall (Attems, 
Jellinger et al. 2011).  
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Production  and  Clearance  of  Aβ  in  CAA 
 Production  of  Aβ  is  a  constitutive  process  and  occurs  during  normal  neuronal  
metabolism in vitro (Haass, Schlossmacher et al. 1992) and in vivo (Seubert, Vigo-
Pelfrey et al. 1992). As described above the APP parent protein is sequentially cleaved by 
enzymes  BACE  and  γ-secretase  to  yield  the  more  abundant  Aβ40  and  to  a  lesser  extent  
Aβ42.  Like  any  other  biologically  active  protein,  Aβ  must  also  be  cleared  and  this  is  
accomplished by several mechanisms either within the parenchyma or transport and 
transcytosis across the blood brain barrier (BBB) (Figure 3). Although it is speculated 
that deficiencies in these clearance mechanisms and not so much the overproduction, 
result  in  the  build  up  of  both  peptides  in  sporadic  forms  of  parenchymal  AD  (Aβ42) and 
CAA  (Aβ40),  it  is  not  yet  known  what  mechanisms  govern  where  the  pathology  will  
locate. Our lab is under the presumption that parenchymal pathology results from 
complete ablation of clearance pathways whereas vascular pathology results from 
inappropriate  transport.  We  are  not  so  much  concerned  with  Aβ  aggregation  itself  as  we  
are  where  Aβ  aggregates  and  how  it  is  shuttled,  as  will  be  evidenced  in  the  data  presented  
below. None-the-less  it  is  important  to  understand  the  mechanisms  that  mediate  Aβ  
clearance.  Below  is  a  description  of  current  insights  into  Aβ  clearance,  which  will  build  a  
foundation for our work and how possible mechanisms our laboratory has uncovered in 
human tissue may further explain secondary vascular pathologies seen in AD with CAA. 
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Figure 3. Diagram  depicting   the   different  mechanisms  of  Aβ   clearance from the brain 
parenchyma.
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Enzymatic Digestion 
Aβ  is  a  ligand  for  several  neuron-derived, zinc-dependent endopeptidases. Such 
enzymes  cleave  Aβ  at  either  a  single  or  at  multiple  sites  resulting  in  smaller  fragments,  
which are much less likely to aggregate. Much work has gone into deciphering the role of 
these peptidases in AD pathogenesis and it is hypothesized that an age-associated decline 
in enzyme levels correlate with plaque load (Akiyama, Kondo et al. 2001, Yasojima, 
Akiyama et al. 2001, Russo, Borghi et al. 2005) and CAA (Miners, Van Helmond et al. 
2006). Examples of enzymes implicated in AD are neprylisin (Nep), insulin-degrading 
enzyme (IDE), matrix metalloproteinases (MMPs), angiotensin-converting enzyme 
(ACE) and endothelin-converting enzyme (ECE). The above examples represent 
endopeptidases usually either cytosolic (IDE) or membrane-bound (ACE, Nep, MMP) 
localized to neurons and most have a secreted form [reviewed in (Miners, Barua et al. 
2011)]. 
Of interest, Nep and IDE localize to the cerebrovasculature. The tunica media and 
endothelium of leptomeningeal and cortical blood vessels both express Nep, which 
negatively  correlates  with  Aβ  levels  in  CAA  even  when  controlling  for  loss  of  SMCs  
(Carpentier, Robitaille et al. 2002). It makes sense, however, that loss of SMCs would 
contribute  to  loss  of  Nep  and  thus  increased  Aβ  deposition. Interestingly, IDE, which is 
present in both endothelium and SMCs, is increased in severe CAA, but shows decreased 
activity (Morelli, Llovera et al. 2004). An increase in IDE could simply be a 
compensatory  response  to  reductions  in  Nep  or  to  increased  Aβ  load  within  the  vessel,  
which is seen in other enzymes such as MMP-2,-3 and -9 and plasminogen activators in 
vitro (Deb, Zhang et al. 1999, Jung, Zhang et al. 2003) and in vivo (Tucker, Kihiko-
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Ehmann et al. 2000). Our lab has found no such evidence of increased levels of these 
proteases (Schrag, unpublished observations). Additionally, it could be surmised that 
increased levels of proteases near the vasculature contribute to vessel break down through 
degradation of the vessel extracellular matrix. In APPswedish mice, a model of CAA, 
MMP-9  was  found  colocalized  with  30%  of  Aβ-laden vessels in the vicinity of the 
endothelium and adjacent to microhemorrhages (Lee, Yin et al. 2003). However, it has 
been observed in human postmortem specimens of MCI cases that membrane-bound (but 
not  cytosolic)  IDE  levels  and  activity  are  reduced  and  negatively  correlated  to  Aβ  levels  
in the hippocampal formation (Zhao, Xiang et al. 2007), a predilection site for early AD 
pathophysiology. It is important to note the differences in AD and CAA manifestation of 
IDE, which could suggest separate disease etiologies—a concept that will be discussed in 
great detail in the conclusion.   
 
Clearance  of  Aβ  Through  the  BBB 
 The  majority  of  the  Aβ  produced  in  the  brain  is  transported  into  peripheral  
circulation though the BBB via SMCs, endothelial cells and pericytes. This is thought to 
be receptor-mediated via transcytosis (Poduslo, Curran et al. 1999). Well described 
clearance receptors include the cell-surface lipoprotein receptor-related protein (LRP-1) 
on SMCs (Deane, Sagare et al. 2008) and P-glycoprotein (PgP or ABCB1) on endothelial 
cells (Lam, Liu et al. 2001). It has been suggested that 70-90% of parenchymal and 
vascular  Aβ  is  cleared  by  circulating  LRP-1 in a peripheral sink effect (Sagare, Deane et 
al. 2007), although the peripheral sink hypothesis has recently been challenged (Walker, 
Pacoma et al. 2013).  A  separate  mechanism  of  BBB  regulation  of  Aβ  levels  is  via  the  
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receptor for advanced glycation  end  products  (RAGE),  which  mediates  Aβ  influx  into  the  
brain parenchyma. Deane et al. (2003) demonstrated that RAGE is increased on the 
cerebral vasculature in AD patients and that increased RAGE on murine blood vessels led 
to increased parenchymal amyloid (Deane, Du Yan et al. 2003). The pathogenic cascade 
in  this  study  did  not  seem  to  lie  with  Aβ,  however.  Instead,  increased  RAGE  resulted  in  
increased generation of pro-inflammatory cytokines and endothelin-1, which mediate 
potent vasoconstriction and hypoperfusion of surrounding brain tissue.  
In addition, LRP-1  may  control  direct  efflux  of  Aβ  through  the  BBB  by  
interaction  with  the  known  LRP  ligands  apoE  and  α2M  (Shibata, Yamada et al. 2000), of 
which both have a shown to have genetic association with increased AD risk (Liao, 
Nitsch et al. 1998, Herz and Marschang 2003, Coon, Myers et al. 2007). LRP-1 levels are 
decreased on cortical blood vessels (Donahue, Flaherty et al. 2006), specifically on SMCs 
(Bell, Deane et al. 2009), isolated from individuals with clinically and pathologically 
confirmed AD. Two interacting transcription factors involved in SMC differentiation, 
serum response factor (SRF) (Miano 2003) and myocardin (MYOCD) (Wang, Chang et 
al. 2001), are paradoxically increased on the same blood vessels compared to control 
vessels. This important finding was extended mechanistically in which the interaction of 
SRF and MYOCD activated sterol regulatory element binding protein-2 (SREBP2), a 
repressor of LRP-1 expression, thus knocking down LRP-1 (Bell, Deane et al. 2009). 
Knock down of SRF or mutation of SREBP2 in human SMC culture ameliorated the 
SREBP2-mediated decrease of LRP-1. This study places the initiating events in AD 
pathophysiology at the vasculature. A decrease in LRP-1  would  result  in  decreased  Aβ  
efflux  leading  to  increased  parenchymal  Aβ  accumulation and possibly deposition within 
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the vasculature. More importantly, increased SRF-MYOCD interaction would lead to 
decreased cerebral blood flow and brain hypoperfusion through increased arterial 
hypercontractility, similar to the effect of RAGE expression described above.   
The  two  mechanisms  of  Aβ  transport  across  the  BBB  offer  targets  to  decrease  
plaque build up within the brain parenchyma and cerebral vasculature. However, it seems 
that targeting RAGE and SRF-MYOCD offers a way to ameliorate vascular contributions 
to AD pathophysiology, which according to these studies may play a much more 
important  role  than  Aβ  accumulation. 
  
Retrograde, Perivascular Drainage 
 A  mechanistically  intriguing  route  of  Aβ  clearance  occurs  through  non-specific 
bulk flow of brain interstitial fluid (ISF). The brain lacks a comparable lymphatic system 
to  the  rest  of  the  body,  so  ISF  must  travel  through  the  parenchyma  to  either  the  brain’s  
surface, where it is then absorbed by arachnoid granulations and into the CSF, which is 
then drained into the jugular vein. A second route consists of retrograde perivascular 
transport through the Virchow-Robin Spaces (VRS). Although the former example makes 
up the majority of bulk flow transport in the human brain (Johanson, Duncan et al. 2008), 
the latter example has more implications for CAA pathophysiology.  
The VRS comprise a functional anatomic compartment associated with 
penetrating cortical arteries, in which the pia mater at the cortical surface is reflected onto 
the abluminal surface of the artery wall in the subarachnoid space (Krahn 1982, 
Hutchings and Weller 1986, Zhang, Inman et al. 1990).  Once  solutes,  including  Aβ,  reach  
the vascular compartment by bulk flow, it is theorized that they are transported up the 
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vessel wall in the VRS via retrograde, pulsatile motion provided by the waves generated 
by contraction and expansion of the artery (Schley, Carare-Nnadi et al. 2006). Based on  
tracer studies in mice, solutes are then found along the basement membrane between 
smooth muscle cells in the arterial media of cortical arterioles and leptomeningeal arteries 
(Carare, Bernardes-Silva et al. 2008) down to the Circle of Willis (Szentistvanyi, Patlak 
et al. 1984).  This  distribution  of  Aβ  intercalating  between  adjacent  SMCs  (Figure  2)  has  
also been shown in human postmortem tissue (Soontornniyomkij, Choi et al. 2010). 
However, at the skull-base solutes drain into the cervical lymphatics before entering 
venous circulation, which explains the lack of CAA on the large subarachnoid arteries 
(Cserr and Knopf 1992).  
The contribution of perivascular drainage to CAA is not yet fully understood. 
Bulk flow and perivascular drainage are very slow (Bell, Sagare et al. 2007) and only 
responsible for about 10-15%  of  Aβ  clearance,  while  the  majority  is  transcytosed across 
the BBB (Shibata, Yamada et al. 2000). Drainage could thus only be a compensatory 
mechanism when other routes fail, (such as loss of LRP-1) which then becomes 
overloaded  resulting  in  both  Type  I  and  Type  II  CAA,  with  backup  of  Aβ  into  the  
parenchyma. Based on the theoretical model of perivascular flow (Schley, Carare-Nnadi 
et al. 2006), aged arteries effected by arteriosclerosis or inflammation would become 
rigid, disrupting their contractile function and thus impeding perivascular flow. It is 
thought  that  Aβ  itself  causes  these changes in SMCs in cortical arteries (Dorr, Sahota et 
al. 2012). This may be true in transgenic animals as the previous study was conducted 
with TgCRND8 mouse model with Swedish and Indiana APP mutations. However wild 
type  Aβ  fails  to  show  the  same  neurotoxic  effect  on  primary  human  SMCs  in  vitro  as  do  
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Dutch and Flemish mutant forms (Davis and Van Nostrand 1996, Wang, Natte et al. 
2000). This begs the question, what entity does result in SMC toxicity and vascular 
fragility  if  it  is  not  Aβ?  We  hypothesize  elements  of  the  innate immune system may 
provide an explanation for vascular fragility. 
 
Microglia  and  the  Complement  Cascade  in  Aβ  Clearance 
The Role of Microglia in Neurodegeneration 
 Microglia are the innate immune cells of the brain. Although first postulated by 
Pio del Rio Hortega around 1920 to be mesodermally-derived (unlike neurons, astrocytes 
and oligodendrocytes), it was not until the 1990s that microglia were established as 
descendants of the myelomonocytic lineage and thus likely of hemangioblastic origin 
(McKercher, Torbett et al. 1996). Unlike adult peripheral macrophages, microglia are 
derived from the primitive yolk sac (Myb-independent) and enter the embryonic 
neuroepithelium around the time neurulation completion as amoeboid in morphology 
(~8.5 days post conception; dpc) (Alliot, Lecain et al. 1991, Bertrand, Jalil et al. 2005). 
Interestingly, newly positioned amoeboid microglia arrive in the neuroectoderm before it 
even becomes vascularized (Monier, Adle-Biassette et al. 2007). Once the newly 
established amoeboid microglia enter the brain, they undergo proliferation, shift their 
morphologic phenotype to a ramified state and diffuse out to essentially cover the entire 
brain in a spatially delineated, grid-like pattern. Constituting approximately 2.5-10% of 
all brain cells (5-20% of neuroglia), microglia number one to every neuron, which does 
suggest a vital role in neuronal development and homeostasis. Recent evidence suggests 
microglia facilitate removal of apoptotic neurons (Sierra, Encinas et al. 2010) and strip 
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dendrites of weakly connected synapses (Paolicelli, Bolasco et al. 2011) during brain 
development. 
In the adult brain, ramified microglia have the ability to react to any number of 
stimuli (Kreutzberg 1996) in a matter of minutes (Morioka, Kalehua et al. 1991), 
mounting  an  immune  response.  Termed  the  “garbage  men”  of  the  brain,  microglia  are  
professional and highly efficient phagocytes, utilizing several methods for engulfing 
debris (Napoli and Neumann 2009, Neumann, Kotter et al. 2009).  
A  caveat  seems  to  arise,  however,  in  their  ability  to  degrade  Aβ.  Although  
microglia  make  use  of  a  plethora  of  phagocytic  receptors  for  Aβ  uptake  (Paresce, Chung 
et al. 1997),  the  majority  of  Aβ  (including  both  fibrillar  and  soluble  forms)  goes  
undigested and is released from the cell. Chung et al. (1999) found that microglia 
phagocytized fAβ  within  three  days.  However,  after  three  days,  intact  Aβ  was  slowly  
released.  In  contrast,  sAβ  was  internalized  and  then  immediately  released  without  much  
degradation (Chung, Brazil et al. 1999). On the other hand, peripheral macrophages in 
culture  can  efficiently  phagocytize  and  degrade  fAβ  from  the  N  terminus  (Majumdar, 
Chung et al. 2008). These findings match early interpretations of the role of microglia in 
plaque  homeostasis  as  Aβ  producers  (Stalder, Deller et al. 2001, Garcia-Alloza, Ferrara et 
al. 2007). The explanation for this weakness of microglia-mediated  Aβ  phagocytosis  may  
either reside in the inherent inactivity of some lysosomal enzymes or to decreased 
microglial lysosomal acidity. Primary murine microglia incubated with mannose-6-
phosphate  tagged  lysosomal  enzymes  showed  enhanced  degradation  of  fAβ  (Majumdar, 
Chung et al. 2008), while microglia activated by macrophage colony stimulating factor or 
IL-6  had  increasingly  acidified  lysosomes,  which  resulted  in  increased  fAβ  digestion  
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(Majumdar, Cruz et al. 2007). A recent hypothesis (Krstic and Knuesel 2012) has been 
put forward, however, that suggests microglia are recruited to the site of neuritic plaques 
to  clear  dead  or  dying  neurons,  not  Aβ,  much  like  they  do  in  the  developing brain 
[reviewed in (Zabel and Kirsch 2013)].  
Another plausible explanation for microglial inadequacies at clearing aggregated 
proteins is simply their age. Microglia, like all other cells in the body, have a 
predetermined lifespan and begin to senesce at older ages. At this point, they may begin 
to become dysfunctional and inappropriately activated to even the smallest stimuli. This 
inappropriate  activation  may  be  due  to  a  process  called  “priming,”  in  which  small  stimuli  
essentially put the cell into a state of alert and any stimuli to follow, regardless of its 
intent, will result in an extremely robust response. Increased levels of human leukocyte 
antigen (HLA) DR on microglia from aged human brains is considered a marker for 
priming in the CNS (Norden and Godbout 2012), however this should be taken with 
caution as many resting microglia also express HLA-DR (Streit, Sammons et al. 2004). 
Instead, microglial dystrophy, which involves any number of morphologic changes to 
microglia (i.e. deramification, beading or fusing), is a sign of microglial senescence and 
ultimately results in fragmentation of microglial cell bodies (Streit 2006). Interestingly, 
Streit et al. (2009) also showed with human histopathology that fragmented microglia 
colocalize with neuronal NFT pathology and that dystrophic microglia precede the 
formation of neuronal degeneration (Streit, Braak et al. 2009). Combining molecular 
phenotype and cell morphology, Perry and colleagues determined that microglia are 
primed by ongoing pathology or age, which manifests as morphological changes and only 
after a second insult (such as peripheral infection) do the cells go through phenotypic 
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switching to express markers of inflammation, such as IL-1β,  IL-6  or  TNFα  (Perry, 
Cunningham et al. 2007).  
The work presented in this thesis combines these hypotheses of microglial 
dysfunction suggesting that microglia in the AD/CAA brain share the morphologic 
characteristics described by Streit; a phenotype that may be dependent on the central 
complement component, C3 and its activation products. 
 
Complement and AD/CAA 
 The complement system is as simple in its design as it is complex in its diversity 
of molecular and cellular functions. Its simplicity stems from its reproducible cascade of 
approximately 30 soluble or membrane-bound proteins involved in the innate immune 
response. The cascade can begin from three proximal points depending on the stimulus, 
but converge on the integral C3 component and ends at the distal cytolytic membrane 
attack complex (MAC), consisting of covalent binding of cleaved C5 (C5b), C6, C7, C8 
and multiple C9 subunits. Two of the three pathways are implicated in AD and CAA. The 
classical pathway begins with activation of the C1 complex by either IgG/IgM antibody-
antigen  complexes  or  Aβ  binding  to  the  C1q  subunit’s  collagen  domain.  This  converts 
two inactive C1r proteases into activated C1r*, which then activates the second pair of 
serine proteases C1s into C1s*. C1s* cleaves inactive C4 into the smaller C4a and larger 
C4b. C4b can then bind C2, allowing its cleavage by C1s*, yielding a larger C2a and a 
smaller C2b fragment. Both C4a and C2b are released into the surrounding milieu. C4b 
binds to C2a, which acts as a C3-convertase (C4b2a) and is able to hydrolyze C3 into the 
smaller C3a anaphylotoxin and the larger C3b fragment. Generation of C3b opens its 
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conserved thioester bond, which can potently react with a hydroxyl or amino group for 
covalent binding to a target. At this point, the alternative pathway can begin with the 
autocatalysis of C3. C3b can then bind to factor D-cleaved factor B forming the 
alternative pathway C3-convertase (C3bBb). Both convertases act to amplify the 
production of the C3b opsonin. The binding of C3b to C4b2a (or C3bBb) results in 
formation of the C5-convertase (C4b2a3b or C3bBb3b), serving the same function to 
amplify production of the small C5a anaphylotoxin and larger C5b from inactive C5. C5b 
is then allowed to insert into a target plasma membrane to initiate MAC formation and 
cytolysis. 
  Complement activation has been implicated in AD pathogenesis since the 
discovery of both classical (McGeer, Akiyama et al. 1989) and alternative (Eikelenboom, 
Hack et al. 1989) complement activation products in senile plaques of AD patients. 
Subsequently,  a  study  by  Rogers  et  al.  (1992)  showed  that  C1q  colocalized  with  Aβ  
plaques in the absence of immunoglobulin staining (the main activator of C1q) and that 
Aβ(1-38),  Aβ(1-28) and APPs 751 can activate C1q in vitro. Additionally, the same study 
demonstrated reactivity for C4d, a product of C4 cleavage, at the site of thioflavin 
staining (Rogers et al 1992), which can only occur in the presence of fully activated C1q. 
This study shed new light  onto  the  possible  toxic  mechanisms  of  Aβ  in  vivo,  which  seem  
dependent on complement activation. Since then, it has been shown that late complement 
activation may indeed be the culprit for neuronal demise in AD. Webster and colleagues 
(1997) demonstrated abundant MAC deposition on NFT-affected neurons and dystrophic 
neurites within neuritic plaques under immune-electron microscopy (Webster, Lue et al. 
1997). Paradoxically, the endogenous MAC inhibitor CD59, was reduced in the 
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hippocampus and frontal cortex of AD post mortem brains compared to controls, along 
with decreased levels of the neuronal synapse marker synaptophysin. Concomitantly, the 
C9 component of MAC was increased in the same brains, suggestive of full MAC 
activation (Yang, Li et al. 2000). One might expect that in a compensatory response to 
increased MAC production, CD59 levels would increase. Interestingly, the same study 
showed  that  as  Aβ  levels  increase,  CD59  mRNA  levels  decrease  in  post  mortem  tissue 
and  Aβ  treated  neurotypic  cells  (Yang, Li et al. 2000). It still remains to be determined 
how  complement  becomes  available  for  Aβ-mediated activation, which cells are 
producing complement and whether complement generation is intended as a protective 
response.  
Further  mechanistic  examination  of  the  complement  cascade’s  role  in  AD  
pathophysiology  yields  interesting  clues  into  complement’s  role  in  AD.  There  does  seem  
to be a dichotomy between the two arms of complement in AD pathophysiology 
(classical and alternative). For example in transgenic mice expressing mutant human APP 
(hAPP), genetic ablation of C1q (APPQ-/-) results in less synaptic disturbances compared 
to hAPP mice sufficient for C1q (Fonseca, Zhou et al. 2004). In addition, a separate study 
by the same group extended these findings, showing that lack of C1q resulted in 
increased C3 levels and a concomitant reduction in neuropathology compared to C1q 
sufficient APP mice (Zhou, Fonseca et al. 2008). Wyss-Coray and colleagues (2002) 
demonstrated the importance of C3 in brain homeostasis in a mouse model of AD crossed 
with a mouse expressing soluble complement receptor-related protein y (sCrry; a 
homologue to the human CR1 protein that blocks the formation of C3b by inhibiting C3 
activation), which yielded significantly reduced levels of activated C3 and its cleavage 
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products (Wyss-Coray, Yan et al. 2002). hAPP/sCrry mice manifested with a higher 
plaque load, altered microglial phenotype and more prominent neuronal loss compared to 
their wild type littermates. A similar study by Maier et al. (2008) corroborated these 
results in C3 knock out mice crossed with hAPP mice (Maier, Peng et al. 2008). 
hAPP;C3-/- mice demonstrated increased AD neuropathology, significant loss of 
hippocampal  neurons  and  an  altered  microglial  phenotype  shifted  towards  an  MΦ2  
(macrophage type 2) phenotype with accompanying increases in the anti-inflammatory 
cytokines IL-4 and IL-10. These studies in aggregate suggest two important roles for 
complement in AD the brain: 1) the classical complement pathway mediated by C1q 
seems to be detrimental to the AD, for reasons not yet fully understood; 2) the C3 
component, and more likely the opsonizing effects of C3b, confers a protective effect 
against AD-associated pathology and cognitive symptoms in mice. 
It  was  previously  mentioned  that  Aβ  can  be  transcytosed  across  the  BBB  into  
peripheral circulation through LRP-1 on vascular SMCs, where it is bound by 
macrophages  or  erythrocytes.  Peripheral  Aβ  transport  is  mediated  by  complement  
receptor 1 (CR1; CD35) and complement C3b on erythrocytes and levels of this complex 
(CR1/C3b/Aβ,  determined  by  immunoprecipitation)  are decreased on erythrocytes from 
AD patients compared to controls (Rogers, Li et al. 2006). CR1 is a type-I 
transmembrane glycoprotein involved in adhesion and phagocytosis of complement-
opsonized complexes and inhibition of C3b generation from C3. Polymorphisms 
delineated by genome-wide associated studies (GWAS) have shown CR1 to be a risk 
gene for AD (Lambert, Heath et al. 2009) and this may be due to a copy number variation 
that codes for a CR1 protein with extra binding sites for C3b (Brouwers, Van 
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Cauwenberghe et al. 2012). However, only preliminary results exist for the role of the 
CR1 protein in AD pathophysiology (Hazrati, Van Cauwenberghe et al. 2012). More 
work will need to be done to translate the GWAS findings into a mechanistic interaction 
between  Aβ,  C3b  and  CR1  and possibly even its sister complement receptor, CR3 
(CD11b/CD18; Mac-1;;  αMβ2  integrin).  It  has  been  shown  that  Aβ  and  C3b  can  be  bound  
by the microglial specific, integrin receptor, CD11b in vitro and in vivo and this can 
mediate  Aβ  clearance  via  phagocytosis (Choucair-Jaafar, Laporte et al. 2011, Fu, Liu et 
al. 2012). Interestingly, sequential interaction between CR1 and CR3 does exist when 
peripheral phagocytes engulf material. CR1 can act as an adhesion molecular to bind 
C3b-opsonized particles. C3b is then cleaved by CR1 into iC3b and the iC3b/particle is 
transferred (on the same cell) to an adjacent CR3 receptor, which acts as the 
phagocytosing effector molecule (Fallman, Andersson et al. 1993). Whether this 
fascinating mechanism occurs on microglia remains to be seen.  
Less is known about the role of complement activation in CAA or vascular 
fragility. There are, however, some interesting possibilities that deserve further 
investigation based on the available observations: 1) activated complement proteins 
associate  with  microvascular  Aβ  lesions  (Verbeek, Otte-Holler et al. 1998, Schrag, 
McAuley et al. 2010) and 2) reactive microglia locate around CAA-affected vessels 
(Maat-Schieman, Rozemuller et al. 1994, Vinters, Natte et al. 1998).  
The data presented in this section lend credence, not only to further study the 
complement pathways in AD pathogenesis, but they also raise further questions. Could a 
similar mechanism of MAC activation on cerebral blood vessels contribute to the demise 
of CAA-affected vasculature? If there is not, is this compensated for by increased levels 
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of CD59? And finally, if microglia  bind  Aβ  through  CR3  and  C3b,  does  this  mechanism  
contribute  to  complement  activation  and  Aβ  deposition  at  the  vessel  wall  in  CAA?   
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Abstract 
Alzheimer’s  disease  (AD)  and  cerebral  amyloid  angiopathy  (CAA)  are  two  
common  pathologies  associated  with  β-amyloid  (Aβ)  accumulation  and  inflammation  in  
the brain; neither is well understood. The objective of this study was to evaluate human 
post mortem brains from AD subjects with purely parenchymal pathology, and those with 
concomitant CAA (and age-matched controls) for differential expression of microglia-
associated  Aβ  ligands  thought  to  mediate  Aβ  clearance  and  their  association  with  
complement activation. Homogenates of brain parenchyma and enriched microvessel 
fractions  from  occipital  cortex  were  probed  for  levels  of  α-2-macroglobulin (2M), C3b, 
membrane attack complex (MAC), and CD11b and immunoprecipitation was used to 
immunoprecipitate (IP) CD11b complexed  with  C3b  and  Aβ.  2M was decreased in 
AD/CAA. Both C3b and MAC were significantly increased in CAA compared to AD-
only  and  controls  and  IP  showed  significantly  increased  CD11b/C3b  complexes  with  Aβ  
in AD/CAA subjects. Confocal microscopy was used to visualize these interactions. 
MAC was associated with CAA affected blood vessels compared to AD-only and control 
vessels.  These  findings  are  consistent  with  microglial  Aβ  binding  via  CD11b  that  delivers  
Aβ  and  C3b  to  blood  vessels  in  AD/CAA,  which  leads  to  Aβ  deposition  and  propagation  
of complement to the cytolytic MAC, possibly leading to vascular fragility. 
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Introduction 
 Alzheimer’s  disease  (AD)  is  the  most  common  neurodegenerative  disorder  among  
people over the age of 65 and is accompanied by some degree of the microvasculopathy 
cerebral amyloid angiopathy (CAA) in 75-90% of cases (15). CAA is characterized by 
the deposition  of  amyloid  beta  (Aβ)  in  the  tunica  adventitia  and  media  of  leptomeningeal  
and penetrating cortical arteries and degeneration of medial vascular smooth muscle, 
resulting in vascular fragility and intracerebral hemorrhage (42, 45). Evidence is 
mounting that CAA plays an important role in the pathogenesis of cognitive deficits 
associated with AD, sometimes through the mechanism of microbleeds or microinfarcts 
(19, 29, 39).  However,  the  mechanisms  responsible  for  this  vascular  Aβ  accumulation,  
smooth muscle loss and fragility have remained speculative and defied therapeutic 
intervention.  
Microglia are the resident immune and phagocytic cells of the nervous system and 
are  known  effectors  of  brain  Aβ  clearance  (17, 47). There is an extensive literature 
describing  the  chemotactic  and  phagocytic  response  of  microglia  to  Aβ  from  studies  on  
human autopsy material, as well as animal and in vitro studies. Microglia are capable of 
binding  and  phagocytosing  Aβ  and  removing  its  breakdown  products  from  the  brain  
parenchyma. In the normal brain, microglia exist in a highly ramified phenotype, 
constantly surveying their environment, probing for tissue architecture abnormalities and 
foreign infiltrates (13). After a pathological insult, microglia shift their phenotype to an 
“activated”  amoeboid-like morphology, expressing a variety of inflammatory and 
receptor proteins (11, 17). Recent studies of human autopsy material suggest that 
microglia become dystrophic and functionally impaired with aging, resulting in immune 
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dysfunction and improper expression of cytokine and receptor profiles (23, 40). This 
theme of age-related alterations in microglial function led us to examine the possible role 
of microglia in the pathogenesis of CAA. 
In addition to the role of microglia, there is evidence for late-complement 
activation on the microvasculature in CAA (25, 34, 36). Complement activation involves 
a series of coordinated protein cleavages and interactions ultimately activating and 
depositing the terminal lytic Membrane Attack Complex (MAC). The MAC is a 
macromolecular protein complex consisting of single components of C5b, C6, C7, C8 
and multiple C9 components forming a pore in target cell membranes, inducing cell lysis. 
MAC formation is initiated by the formation of a C5-convertase (any of a variety of 
complexes containing C3b).  Complement C3b, a cleavage product of the central C3 
component, is a high-affinity  ligand  for  β-amyloid  and  can  act  as  an  opsonin  of  Aβ  
plaques (7, 35).  This  complex  (C3b/Aβ)  binds  to  Complement  Receptor  1  (CR1) on 
erythrocytes,  which  appears  to  be  involved  in  clearance  of  Aβ  in  the  peripheral  
circulation (35). CD11b (CR3) a homolog of CR1, which is selectively expressed on 
microglia in the brain, binds to C3b and is implicated in the adhesive interactions of 
monocytes, macrophages, and granulocytes (17, 30) as well as complement coated 
particles,  and  binds  Aβ  in  a  yeast  model  (8). We hypothesized that CD11b may serve as a 
cell-surface  receptor  for  the  complex  of  Aβ  and  C3b  and  may  be  a  mechanism  of  Aβ  
clearance from the parenchyma and complement activation on vascular elements.  
Finally,  Apolipoprotein  E  ε4  (ApoE  ε4),  a  genetic  risk  factor  for  AD,  is  known  to  activate  
the complement cascade (26), so we additionally asked whether or not the apoE 
E4/CD11b/C3b/Aβ  complex occurred on human microglia in human postmortem tissue. 
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This study of human, post-mortem brains with CAA has led to the identification of a 
microglial cell-surface  complex  that  appears  to  be  involved  in  Aβ  clearance  in  CAA  and  
may explain the late complement  activation  on  the  vessel  wall  at  the  site  of  Aβ  
deposition.  
  
Methods  
Tissue Selection 
Post  mortem  tissue  was  obtained  from  the  Alzheimer’s  Disease  Research  Center  
Brain Bank at the University of California, Los Angeles.  All patients or their surrogates 
consented to participate in research protocols prior to tissue donation, and the study was 
approved by the Institutional Review Board of Loma Linda University Medical Center 
(approval #54174). Patient demographics are described in Table 1. Both frozen tissue 
specimens and fixed tissues were available for study. Neuropathologic examination at the 
time of autopsy included Braak and Braak staging of AD and Vonsattel grading of CAA 
pathology (6, 12). CAA staging of CAA severity is as follows: stage 1- β-amyloid 
deposition limited to the basement membrane of arterioles and primarily involving 
leptomeningeal vessels; stage 2- β-amyloid deposited between vascular smooth muscle 
cells and pathology extends to penetrating arterioles and stage 3- β-amyloid largely 
replaces vascular smooth muscle in arterioles. Specimens were graded based on the 
majority of vessels displaying the respective Vonsattel stage. Microaneurysms and 
microhemorrhages often occur with Vonsattel stage 3 CAA, however, microhemorrhages 
were rare in this cohort. Additionally, no patients were included in this study with fatal 
lobar or intracerebral hemorrhage.   
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Frozen tissue was isolated from the occipital lobe for five groups of patients; four 
samples were obtained from an aged, neurological control group (n=4), along with four 
AD samples without evidence of significant CAA (Vonsattel grades 0-1) and sixteen AD 
samples with varying degrees of CAA, grouped into mild (n=8), moderate (n=4) and 
severe (n=4) CAA (grade 3) (ADmiCAA, ADmodCAA and ADsevCAA, respectively).   
 
Microvessel Enrichment 
Brain microvessels were isolated from the occipital lobe of frozen postmortem 
brain tissue from four cases in each group. A homogenization buffer was prepared over 
ice consisting of 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 300 mM sucrose, 2 mM 
EDTA and protease inhibitor cocktail. Samples were homogenized with three to four 
vertical strokes of a Teflon pestle in a glass tube, the homogenate then poured over a 72 
m mesh sieve (Gelman Sciences) with microvessels collected by flushing the sieve with 
ice cold homogenization buffer. Homogenates containing microvessels were then poured 
into 20 mL Falcon tubes, centrifuged for 15 minutes at 2,000 rpm, and vessels 
concentrated into homogenization buffer and verified by examining a sample fixed with 
100% ethanol on charged glass slides (Fisher Scientific, Pennsylvania). Samples were 
sonicated 3 times to further homogenize blood vessels and protein quantification cached 
by the Bradford assay (Pierce Laboratories, Illinois). 
 
Western Blot Analysis 
Protein  levels  of  complement  components  and  regulators  and  α2M on occipital 
lobe vessels and occipital lobe whole brain tissue were determined by denaturing SDS-
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PAGE and western blot. Briefly, tissue samples were isolated containing roughly equal 
proportions of white and grey matter from the occipital lobe, and homogenized in an ice 
cold sucrose buffer containing a protease inhibitor cocktail.  Tissue was further 
homogenized in a fitted Teflon pestle in a glass homogenization tube. Nuclear debris was 
cleared from the suspension by centrifugation at 1000g for 15 minutes and total protein 
concentration was determined in the supernatant by the Bradford assay (Pierce 
Laboratories, Illinois).  Samples were prepared for electrophoresis by adding 25% v/v 
loading buffer (Invitrogen, California) and 10% v/v beta-mercaptoethanol and heating at 
95°C for ten minutes. Ten micrograms of total protein were loaded into each lane of a 
10% polyacrylamide gel and electrophoresed at 100V in a MiniProtean Tetra System 
(BioRad Laboratories, California). The proteins were then transferred to a nitrocellulose 
membrane at 30V for four hours. The resulting blot was blocked in an albumin-based 
blocking buffer (Invitrogen) and probed with either beta-actin (mouse monoclonal; 
1:1000),    α2M  (rabbit  polyclonal;;  1:500),  CD11b  (rabbit  polyclonal;;  1:500),  C3b  (mouse  
monoclonal; 1:500), C6 (mouse monoclonal; 1:500), C5b-9 (rabbit polyclonal; 1:500), 
CD59 (mouse monoclonal; 1:500) and apoE E4 (mouse monoclonal; 1:500) antibodies 
(all  from  Abcam)  and  β-amyloid 1-16 (clone AB 10) (mouse monoclonal; 1:1000; 
Millipore). After an overnight incubation at 4°C, blots were thoroughly washed with TBS 
buffer containing 0.05% Tween-20 and a fluorescently labeled goat anti-mouse or rabbit 
secondary (IRDye, Licor) was applied. After two-hour incubation, blots were washed and 
visualized on an Odyssey Infrared Imaging System (Licor Biosciences, Nebraska). 
Optical density was determined using Odyssey 2.0 software. Data was collected as the 
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relative intensity of the band of interest compared to the corresponding loading control 
band  of  β-actin.  
 
Immunohistochemistry 
 Paraffin-embedded, formalin fixed sections of occipital lobe tissue were 
deparaffinized in two exchanges of xylene and rehydrated in serial exchanges of ethanol. 
Antigen retrieval was performed by heating sections in a microwave on high power (3x at 
90 seconds each) in a 10 mM citrate buffer. The sections were then treated with 1% 
hydrogen peroxide in PBS to block endogenous peroxidase activity, incubated with a 
blocking solution of 4% normal serum in PBS, and incubated with the primary antibody 
of choice overnight at 4°C. After washing with PBS, sections were incubated with a HRP 
conjugated secondary antibody for 2 h, washed in additional exchanges of PBS and 
treated with diaminobenzidine/hydrogen peroxide (DAB) for 10 min (Vector 
Laboratories), followed by hematoxylin as a counterstain. They were then rinsed for 3 
min in PBS, dehydrated through serial alcohols, cleared in xylene and coverslipped with 
mounting resin (Permount, Fisher). The antibody used was against C6 (mouse 
monoclonal 1:500) (Abcam). 
 Co-immunofluorescent studies were prepared on sections as previously 
mentioned. After blocking with 4% normal serum in PBS, slides were incubated with 
primary  antibodies  against  alpha  smooth  muscle  actin  (αSMA)  (mouse  polyclonal;;  
1:200), C5b-9 (rabbit polyclonal; 1:500) (Abcam), CD11b (rabbit polyclonal; 1:500) 
(Abcam)  and  an  antibody  against  Aβ40 (mouse monoclonal; 1:1000) (Abiotec). Sections 
were similarly prepared with 0.01% Thioflavin S, but washed in two exchanges of 70% 
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ethanol before application of DAPI. After overnight incubation, slides were washed and 
incubated with secondary antibody conjugated to either Texas Red or FITC for two hours 
and then washed. Sections were stained with DAPI (Vector Laboratories) and visualized 
by a LSM 710 confocal microscope (Zeiss). Negative controls were prepared in the same 
fashion, but lacked the incubation step with primary antibody. 
 
Immunoprecipitation 
Co-immunoprecipitation was done on occipital lobe whole-brain homogenates; 
groups consisted of controls, AD only and AD with severe CAA (n=4 in all groups). 
Briefly,  magnetic  Dynabeads  (Invitrogen)  were  resuspended  and  50  μl  was  transferred to 
12 tubes. Beads were separated from supernatant on a magnet and the supernatant was 
removed.  5  μl  of  anti-CD11b  antibody  (1  μg/μl;;  Abcam)  was  diluted  in  200  μl  1x  PBS  
with .02% Tween-20 (pH 7.4) and each tube was incubated for 10 minutes with rotation 
at room temperature. Tubes were then placed on the magnet and the supernatant was 
removed. The bead-Antibody  complex  was  resuspended  in  200  μl  PBS  with  Tween-20 
and washed with gentle agitation. Tubes were placed on the magnet and the supernatant 
was removed. Samples from control, AD-only and AD with CAA (n=4 in each group) 
were added to the bead-antibody  complex  at  150  μl  and  incubated  with  gentle  agitation  at  
room temperature for 30 minutes. Tubes were then placed on the magnet and the 
supernatant was transferred to a clean tube for further analysis. The beads-antibody-
antigen  complex  was  washed  three  times  using  200  μl  of  1x  PBS  with  gentle  agitation.  
The  complex  was  resuspended  in  100  μl  of  1x  PBS  and  transferred  to  clean  tubes  to  avoid  
co-elution of proteins bound to the tube wall. Tubes were placed on the magnet and the 
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supernatant  removed,  followed  by  addition  of  20  μl  non-denaturing elution buffer (50 
mM glycine pH 2.8) and incubated for 2 minutes. Tubes were placed on the magnet and 
the supernatant was transferred to a clean tube and prepared for western blot as described 
in the Western Blot section.  
 
Statistical Analysis 
 Data are reported as mean ± standard error. Because of the small sample size, the 
data did not fit a normal distribution, so differences between groups were assessed by 
Kruskal-Wallis non-parametric ANOVA. Significant differences between groups were 
then reported by post-hoc  analysis.  Genotyping  analysis  was  assessed  with  Fischer’s  
exact  test  for  categorical  data.  α<0.05  was  taken  as  a  significant  result. 
 
Results 
APOE4 and CR1 genotyping analysis 
 Genotyping of our patient cohort did not show the usual trend for risk of AD or 
CAA with APOE4,  in  which  even  only  one  ε4  allele  can  significantly  increase  the  risk  of  
both  AD  and  CAA.  The  majority  of  patients  in  all  groups  were  homozygous  for  the  ε3  
allele,  with  at  least  one  case  harboring  one  ε4  allele  in  each  group. CR1 genotyping was 
done in light of recent findings by Biffi et al. (5), in which individuals homozygous for 
the A allele showed a higher risk for intracerebral hemorrhage (ICH) due to CAA 
compared to heterozygous (A/G) or homozygous neutral (G/G). The product of the CR1 
gene, CR1, binds to and cleaves C3b into inactive components iC3b and C3c (18). In our 
cohort, 12/16 (75%) of CAA cases were homozygous A/A (Table 1), the major risk 
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genotype for CAA associated ICH (5). On the other hand, only one case was homozygous 
A/A in the AD-only group and none of the controls were homozygous A/A (Table 1). 
When all CAA cases were compared to all non-CAA cases, the association of CAA 
pathology to the A/A genotype was highly significant (P=0.006). Genotype data could 
not be obtained for patient 20.  
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Table 1 Patient Demographics 
Case# Sex Braak & Braak Stage 
APOE 
status 
CR1 
status§ 
Age 
(y) 
PMI 
(h) 
Controls 
1 F NP ε3/ε4 A/G 47 7 
2 F NP ε3/ε3 A/G 42 22 
3 F NP ε3/ε3 A/G 81 23 
4 M NP ε3/ε3 A/G 70 23 
AD-only 
5 M VI ε3/ε4 A/G 80 22 
6 F VI ε3/ε3 A/G 81 6.5 
7 M VI ε3/ε3 A/G 89 15 
8 M VI ε3/ε4 A/A 81 9.5 
AD mild CAA 
9 F V ε3/ε3 A/G 79 6 
10 F V/VI ε3/ε3 A/A 91 3.5 
11 F VI ε3/ε3 A/G 89 24 
12 M V/VI ε3/ε3 A/A 82 16 
13 F VI ε3/ε4 A/A 97 12 
14 F VI ε3/ε3 A/A 73 13 
15 F VI ε3/ε4 A/G 81 24 
16 M VI ε3/ε3 A/A 95 22 
AD moderate CAA 
17 M V/VI ε3/ε3 A/A 82 5 
18 F VI ε3/ε3 A/A 96 7 
19 F VI ε3/ε3 A/A 81 11 
20 M VI -- -- 83 12 
AD severe CAA 
21 F VI ε3/ε4 A/A 88 38 
22 F VI ε4/ε4 A/A 71 20 
23 F VI ε3/ε3 A/A 83 6 
24 F VI ε3/ε3 A/A 69 18 
NP=No Pathological Abnormality; PMI = Post mortem interval; y=Years; 
h=Hours; M=Male; F=Female 
§The CR1 A/A allele was significantly associated with CAA cases versus 
non-CAA cases, P = 0.006 
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2M and C3b levels in occipital lobe 
 Two  different  Aβ  receptor/ligand  complexes  were  studied  in  our  post-mortem 
brains; the well recognized LRP1/2M  /Aβ  (14, 27, 28, 37) and a new cell surface 
complex,  CD11b/C3b/Aβ.  A  role  for  these  adhesion  molecules  (2M and C3) in amyloid 
clearance is recognized, but yet to be fully elucidated. We report for the first time that 
levels of both 2M  and  C3b,  two  previously  indicated  Aβ  chaperones  (28, 44), differ in 
the AD-only and AD/CAA brain, suggesting different phenotypes between the two 
diseases. 2M showed a significant difference between groups (H=13.5, 4 d.f., P=0.009; 
Figure 4a) and was significantly decreased in ADmiCAA, ADmodCAA and ADsevCAA 
as compared to controls (P=0.04, P=0.02 and P=0.02, respectively) and to AD-only (P 
=0.01, P=0.02 and P=0.02, respectively; Figure 4a). C3b also showed a significant 
difference between groups (H=12.5, 4 d.f., P=0.01) and was significantly increased in the 
same cases compared to controls (P=0.006, P=0.02 and P=0.02; Figure 4b) and only 
marginally increased in ADmodCAA and ADsevCAA compared to AD-only (Figure 4b). 
Changes in both 2M and C3b additionally showed cross-sectional trends as CAA 
pathology progressed: trending decrease for 2M (Figure 4a) and trending increase for 
C3b, although this tapered off in ADsevCAA cases (Figure 4b).
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Figure 4. Western blot analysis of human occipital lobe parenchyma (whole brain 
homogenate) in cases classified as control (n=4), AD-only (n=4) and AD/CAA. AD/CAA 
cases were further categorized into ADmiCAA (n=8), ADmodCAA (n=4) and 
ADsevCAA (n=4). a Analysis  of  α2M,  a  major  chaperone  of  the  Aβ  peptide,  showed  a  
significant decrease in mild, moderate and severe CAA compared to control and pure 
AD. b Analysis   of   C3b,   the   ligand   for   CD11b   and   opsonin   of   the   Aβ   peptide,   was  
significantly increased across the spectrum of CAA cases from mild, moderate and severe 
compared to controls, while moderate and severe CAA were both significantly increased 
from pure AD. Molecular weights of proteins are in parentheses. *P < 0.05; **P < 0.01. 
Data represented as mean ± S.E.M. Relative   abundance   is   the   ratio   of   α2M   and   C3b:  
beta-actin as optical density. 
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Microglial	  Aβ	  binding	  via	  CD11b 
 
Confocal fluorescent evaluations of fixed occipital lobe grey matter from each of 
the 12 brains (4 each of AD with severe CAA, AD-only, and control) showed a consistent 
pattern of CAA-specific  microglial  Aβ  protein:protein  interactions.  Interactions  were   
identified by FITC conjugated secondary antibodies to localize CD11b (green) (Fig. 5a) 
and  a  Texas  Red  conjugated  secondary  antibody  to  localize  Aβ40 (red). Nuclei are 
identified  by  DAPI  (blue).  All  AD/CAA  CD11b+  microglia  colocalized  with  Aβ40 on 
ramified processes (Figure 5a insets) in contrast to the primarily intracellular co-
localization  of  CD11b  and  Aβ  in  the  AD-only cases. Only minimal colocalization on 
process-like projections in control brains was observed. Identical patterns of 
colocalization were found in all brains (n = 4 for each group). This consistent observation 
has  led  to  the  hypothesis  that  a  microglial  Aβ  binding  mechanism  causes  downstream  
focal  Aβ  vascular  complement  activation  (3b)  and  MAC  generation  in  AD/CAA.  
Representative 3D z-stack micrographs  show  the  consistently  different  Aβ  distribution  
found on microglial processes colocalized with CD11b in AD/CAA (arrowheads) 
compared to AD-only and controls (Figure 5b). Negative controls done with the same 
protocol, but without primary antibody validated the staining (Appendix; Supplementary 
Figure 1).  
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Co-immunoprecipitation of CD11b 
 Co-immunoprecipitation of CD11b from occipital lobe whole brain homogenate 
yielded relatively equal abundance of CD11b protein on SDS-PAGE western blot 
analysis in all three groups (Figure 6a). C3b was significantly increased when CD11b 
containing supernatant was analyzed with western blot analysis in cases of AD/CAA 
compared to both controls and AD-only (H=9.8, 2 d.f., P=0.007; P=0.02 and P =0.02, 
respectively; Figure 6a, 6b).  
 Since  the  APOE  ε4  allele  is  the  major  substantiated  genetic  risk  factor  for  non-
hereditary AD and CAA and the E4 isotype has been shown to potentiate complement 
activation in vitro (26), we chose to determine if it was apart of the CD11b/C3b complex. 
We found that apoE4 was bound to CD11b upon immunoprecipitation; however, it 
showed no statistical significance between groups (Figure 6b). This will need further 
testing in culture in order to confirm that when apoE E4 is complexed with CD11b and 
C3b, potentiation of complement activation occurs and that this is what causes increased 
vascular fragility secondary to MAC deposition.  
Further analysis of CD11b containing supernatant showed increased (albeit not 
significant) levels  of  monomeric  and  dimeric  Aβ bound to microglial CD11b in AD/CAA 
compared to AD-only and controls (Figure 6a, 6d, 6e). These data are in agreement with 
our  confocal  data,  where  we  observed  that  in  every  case,  CD11b  colocalizes  with  Aβ40. 
However, it appears  that  only  in  AD/CAA  does  CD11b  significantly  bind  to  Aβ  through  
C3b, thus delivering active complement to the cerebral vasculature, setting up 
downstream MAC activation.
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Figure 5. Representative confocal micrographs of fixed human occipital lobe tissue. 
Images were taken at 630x magnification and immunostained for a CD11b (n=4 for each 
group) and colocalized with an anti-Aβ40 antibody. A FITC conjugated secondary 
antibody was used for CD11b (green) and a Texas Red conjugated secondary antibody 
was  used  for  Aβ40 (red).  Nuclei were stained with DAPI (blue). b Representative Z-stack 
images  of  microglia  colocalized  for  CD11b  and  Aβ40. Panels show colocalized images in 
which microglial nuclei  are  stained  with  DAPI  and  colocalization  of  CD11b  and  Aβ40 is 
stained yellow/orange. Note  the  colocalization  of  CD11b  with  Aβ40 in punctate densities 
at the plasma membrane in AD/CAA (arrowheads), rather than the perinuclear, 
phagocytic vesicle distribution as seen in AD-only cases. Controls show only faint 
colocalization  for  CD11b  and  Aβ40 that appear to localize to microglial processes. 
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Figure 6. Co-Immunoprecipitation of CD11b. After CD11b immobilization and 
incubation with occipital lobe whole brain homogenate, western blots were performed on 
CD11b containing supernatant and probed for a C3b,  ApoE4,  Aβ  to  measure  the  relative  
abundance of the CD11b/C3b/Aβ   complex   in   each   case.   b AD/CAA had significantly 
higher C3b bound to CD11b compared to both controls and AD-only. c ApoE4 showed 
no difference between groups. d-e Western analysis shows a non-significant increasing 
trend   in   the   binding   of   Aβ  monomers or dimers by CD11b in AD/CAA compared to 
controls and AD only. Molecular weights of proteins are in parentheses. *P < 0.05. Data 
represented as mean ± S.E.M. Relative abundance is the ratio of the target protein: 
CD11b containing supernatant as optical density. 
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In order to confirm binding, we performed the reverse immunoprecipitation on the 
same  samples  for  C3b,  apoE4  and  Aβ  and  performed  western  blots  for  CD11b  
(Appendix; Supplementary Figure 2).  
 
MAC on occipital lobe cerebral vasculature 
 The  evidence  for  binding  of  Aβ  via  the  CD11b/C3b  complex  leading  to  MAC  
activation on vascular smooth muscle cells at the vessel wall during microglial clearance 
in AD/CAA was further evaluated on CAA affected microvasculature by both western 
blot and immunofluorescence for C5b-9 deposition. C5b-9 was significantly different 
between groups (H=6, 2 d.f., P=0.05). C5b-9 was significantly increased when compared 
to both control and AD-only vessels in a microvessel enrichment preparation from the 
occipital lobe (P=0.02 and P=0.03; Figure 7a). Additionally, we probed the enriched 
microvessel fraction for CD59, an endogenous regulator of late complement activation by 
inhibiting the binding of C8 and C9 of the MAC (20), which has shown to be decreased 
in the brain parenchyma in AD (49). We found a decreasing trend in CD59 on blood 
vessels of AD/CAA cases compared to AD-only cases, which parallels the increased 
MAC deposition on the same AD/CAA vessels (Figure 7b).  
  
 58 
Immunofluorescent studies showed C5b-9 on AD/CAA vessels colocalized with 
thioflavin staining, where as control and AD-only vessels lacked such staining (Figure 8). 
Negative controls without primary antibody were used to verify the specificity of 
fluorescent staining (Appendix; Supplementary Figure 3). Additionally, MAC localized 
to the vicinity of smooth muscle cells in a case of mild CAA with co-
immunofluorescence staining of C5b-9  and  αSMA  (Figure  9).  Western  blot  analysis  for  
C6, an integral component of the MAC, showed significantly increased levels in the 
enriched microvessel fraction in AD/CAA cases compared to controls (Figure 10a). 
Immunohistochemical analysis showed robust staining on AD/CAA vessels (Figure 10b), 
which selectively localized to the muscular layer of leptomeningeal arteries (Figure 10c). 
This staining is almost exclusively limited to leptomeningeal arteries and cortical 
arterioles in the grey matter, while the white matter is almost completely spared (Figure 
10d-e) -- a finding that matches the pattern of CAA involving leptomeningeal and 
penetrating cortical arterioles, sparing deeper white matter arterioles (43). 
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Figure 7. Western blot for C5b-9 and CD59 on isolated cerebral blood vessels. a C5b-9 
was significantly increased on isolated AD/CAA vessels compared to both controls and 
AD-only vessels. b CD59 showed a trending decrease on occipital blood vessels of 
AD/CAA cases compared to the control and AD-only groups. *P < 0.05; Molecular 
weights of proteins are in parentheses. **P < 0.01. Data represented as mean ± S.E.M. 
Relative abundance is the ratio of C5b-9 and CD59:beta-actin as optical density. 
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Figure 8. Representative confocal micrographs of fixed human occipital lobe tissue for 
C5b-9 and fibrillar amyloid on cerebral blood vessels. Images were acquired at 100x and 
immunostained for C5b-9 (MAC). A Dylight 550 secondary was used for visualization of 
MAC (red) and 0.01% Thioflavin S was used to visualize amyloid (green). Nuclei were 
stained with DAPI (blue). MAC and amyloid staining colocalize on cortical blood vessels 
in AD/CAA, which is absent in controls and AD-only  sections.  Scale  bar  =  400  μm. 
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Figure 9. Representative images of C5b-9  (MAC)  staining  (red)  colocalized  with  αSMA  
(green) on a cortical arteriole in a case of mild CAA. Scale bar = 30 μm. 
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Figure 10. Western blot and immunohistochemistry for C6 on cerebral blood vessels. a 
C6 is significantly increased on AD/CAA occipital blood vessels compared to controls (n 
= 4 for each group). b Representative image of fixed human brain shows robust C6 
staining of cortical arterioles in grey matter (400x magnification). c C6 selectively 
localizes to the muscular layer of leptomeningeal arteries (dark brown). d Representative 
image of C6 staining on grey matter arterioles in a case of AD/CAA (100x 
magnification). e Representative image of difference in C6 staining on grey matter 
arterioles (GM) versus lack of staining on white matter arterioles delineated by the black 
line (40x magnification). Molecular weights of proteins are in parentheses. *P < 0.05. 
Data represented as mean ± S.E.M. Relative abundance is the ratio of the C6:beta-actin as 
optical density. 
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Discussion 
 In  this  study  we  present  the  hypothesis  that  Aβ  clearance  in  AD  subjects  with  
CAA is distinct from that in AD subjects lacking CAA, and is mediated by microglial 
CD11b  binding  to  extracellular  C3b/Aβ  complexes  and  delivering  both  active  C3b  and  
Aβ  to  the  microvasculature, resulting in late complement activation.  We evaluated 
whether observations from human post mortem occipital lobe tissue from subjects with 
varying degrees of CAA were consistent with this hypothesis. The complex 
CD11b/C3b/Aβ  is  found  only in cases of AD/CAA and not in control and AD cases 
lacking CAA. This process occurs with a concomitant reduction in 2M,  a  known  Aβ  
chaperone  and  likely  a  major  mediator  of  microglial  Aβ  clearance  in  normal  brain  and  in  
AD-only (14). This CAA specific microglia  shift  in  Aβ  binding/clearance  seems  to  be  
associated with cytolytic MAC deposition on leptomeningeal and penetrating cortical 
arterioles  in  the  pattern  of  vascular  Aβ  deposition. 
Several studies have implicated the LRP1/2M  complex  in  normal  Aβ  binding 
and clearance from the brain (21, 27, 28). Additionally, it has been shown that activated 
2M  is  capable  of  blocking  the  formation  of  Aβ  fibrils  in vitro (51). In comparison to the 
observation of an age-dependent decrease in LRP1 (with no change in 2M levels) on 
vessels in an AD mouse model (37) and in human AD postmortem tissue (4, 9), we found 
a significant decrease in 2M as the severity of CAA worsened compared to AD-only 
and  controls.  The  results  from  these  studies  and  ours  suggest  a  faulty  Aβ  clearance 
mechanism that involves both vascular (LRP1) and parenchymal (2M) entities in the 
pathogenesis  of  cerebral  vascular  accumulation  of  Aβ. 
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The complement cascade and in particular, the C3b cleavage product of C3, has 
also  been  speculated  to  be  involved  in  Aβ  clearance  and  degradation  (2). Blocking the 
complement cascade at C3 is thought to result in increased AD pathology, 
neurodegeneration and an altered microglial phenotype (24, 48). Interestingly, with a 
decrease in 2M in our cohort of AD with CAA cases, we also observed a concomitant 
increase in C3b in the same cases compared to both controls and pure AD cases. This is 
mirrored by an increase in the C3b receptor, CD11b, on microglia in both human AD 
tissue (3) and mouse models of AD (10). This seems to be a compensatory mechanism, as 
if the decrease in LRP1/2M is driving a shift towards increased CD11b/C3b to mediate 
Aβ  clearance. 
The unique mechanism implied from this human post mortem study could explain 
vascular  Aβ40 deposition  based  on  the  cell  surface  localization  of  CD11b/Aβ40 on 
microglia in CAA cases rather than the intracellular localization of this complex in AD-
only cases, as also demonstrated by Adolfsson et al. (1). This suggests the complex may 
be  subject  to  lysosomal  degradation  before  it  reaches  the  vascular  tree.  Aβ  and  C3b  
retained on the cell-surface are presumably transported to the vasculature intact in CAA, 
facilitating both amyloid deposition and late-complement activation. Control brain 
microglia  showed  an  even  more  intriguing  Aβ  distribution.  CD11b/Aβ  colocalization  
seemed to appear at the ends of microglial processes, which is suggestive of unchallenged 
microglial phagocytosis in a healthy brain (38, 41). Although it has not been confirmed 
experimentally,  this  “ball  and  chain”  mechanism  of  endocytosis  by  ramified  microglia  
may  represent  efficient  Aβ  removal  in  the  healthy  brain  (41). This observation is 
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consistent with work by Liu et al. (22) who  also  demonstrated  Aβ42 localizing to 
vesicular structures within microglial processes.    
The  implications  of  our  findings  of  CD11b  binding  Aβ  in  the  presence  of  C3b  in  
cases with CAA may explain the visualization of MAC on penetrating cortical arterioles 
and correlation of CAA affected vessels and microbleeds (36). If microglia in AD cases 
with CAA are binding amyloid through the CD11b receptor via C3b on their cell surface, 
this would allow the delivery of activated complement to the vessel wall allowing for the 
propagation towards MAC deposition on vascular smooth muscle cells. The immune 
system has several mechanisms by which to check the activation of complement. CD59 is 
a glycosylphosphatidylinositol (GPI) anchored glycoprotein that binds the C8 component 
and inhibits addition of C9 and thus MAC deposition. Several studies have shown that 
CD59 is decreased in the AD brain (49, 50). We found a non-significant decrease in 
CD59 on isolated vessels from AD/CAA cases, which could explain the inability of 
CAA-affected vessels to protect against MAC deposition and why vessels in AD cases 
lacking CAA are not affected despite increased parenchymal MAC loads.  
Additionally, validation of our biochemical findings can be found in a recent 
genetic study. A variation at rs6656401 on the A allele of the CR1 gene seems to confer 
risk for CAA associated ICH (5). 80% of the CAA cases in our cohort were homozygous 
for the risk allele, to which our protein data matches well with respect to parenchymal 
C3b levels and MAC levels on cerebral blood vessels. Patients with the CR1 variant 
might be at an increased risk for CAA associated ICH because of the inability of CR1 to 
effectively inactivate C3b, thus allowing its uninhibited propagation to the terminal lytic 
MAC. This has been shown experimentally in a mouse model of multiple sclerosis. 
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Ramaglia et al. (33) demonstrated that microglia became primed and pro-inflammatory as 
a result of CD11b/C3b binding after knockout of the mouse homolog of CR1. Increased 
levels  of  activated  C3b  could  then  provide  a  ligand  for  the  binding  of  Aβ  to  CD11b  on  
microglia.  Upon  clearance  of  this  complex,  microglia  deposit  both  Aβ  and  C3b  near  the  
vascular smooth muscle cells resulting in CAA and propagation of the complement 
cascade to MAC and thus the generation of focal microbleeds (Figure 11).  
A  final  point  of  interest  is  the  relationship  of  these  findings  to  the  topic  of  Aβ  
immunotherapy. Immunotherapy has been tested in numerous pre-clinical studies and a 
clinical  trial.  While  it  appears  to  be  successful  in  clearing  parenchymal  Aβ  deposits,  it  
exacerbates  vascular  Aβ  pathology  and  has  an  equivocal  effect  on  cognition  (31, 32, 46). 
The introduction of an anti-Aβ  antibody  to  the  microglial  Aβ  clearance  pathways 
discussed here would be expected to favor clearance through classical complement 
activation and the C3b/CD11b pathway. This may be well-tolerated in subjects who 
primarily  clear  Aβ  through  non-complement activating mechanisms, but in subjects who 
phenotypically  accumulate  Aβ  in  the  vasculature,  this  would  be  expected  to  worsen  the  
pathology. If this hypothesis is accurate, it is potentially relevant therapeutically, because 
possible CAA can be diagnosed based on the extent of Pittsburgh Compound B retention 
in the occipital lobe on positron emission tomography imaging (16) and subjects with 
evidence of significant CAA could be removed from future trials of anti-Aβ  
immunotherapy.
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Figure 11. Proposed mechanism of MAC and Aβ  deposition  in  CAA  pathogenesis.  a In the 
healthy  brain,  activated  microglia  become  amoeboid  and  clear  Aβ  through  phagocytosis  via  α2M  
and LRP-1. b In AD with CAA, LRP-1  and  α2M  are  both  decreased  in  human  tissue,  resulting  in  
the compensatory mechanism of clearance involving C3b-mediated   opsonization   of   Aβ   and  
binding by CD11b on microglia (1). This could be exacerbated if the variant in the CR1 gene 
negatively effects C3b homeostasis, which could result in the inability to inactivate C3b, leading 
to its accumulation.  Upon  delivery  of  the  complex  to  cerebral  blood  vessels  for  clearance  (2),  Aβ  
may become deposited in the vessel wall due to lack of proper phagocytosis (3) and C3b is 
allowed to propagate activation to the MAC (4), which would be even more pronounced with 
decreased defense mechanisms such as CD59 (5). The ultimate result is deposition of amyloid on 
the blood vessel wall and complement-mediated cell lysis , both leading to hallmarks of this 
vasculopathy, CAA and microbleeds, respectively. 
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Although this study is observational and therefore cannot conclusively define 
disease mechanisms, these data point to possible explanations for: 1) complement 
activation on CAA affected vasculature, 2) vascular fragility in CAA, 3) immunotherapy 
exacerbation of the CAA phenotype, and 4) the importance of understanding and 
reporting  pathologic  phenotypes  in  studies  of  human  Alzheimer’s  disease.  These  data  
also point to the late complement cascade as a potential therapeutic target for the sub-type 
of AD with CAA.  More work is planned to delineate these mechanisms in vitro and 
determine how apoE4 may play a role in directing enhanced complement activation to 
cerebral blood vessels. Additionally, follow up studies are warranted in order to better 
understand the potential mechanisms described here in other types of CAA, such as the 
less frequent inflammatory CAA and pure CAA without AD changes, and if the large 
lobar hemorrhages associated with CAA pathology are the result of complement-
mediated vascular fragility. 
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CHAPTER THREE 
 
COMPLEMENT  RECEPTOR  1  IN  ALZHEIMER’S  DISEASE  AND  
CEREBRAL AMYLOID ANGIOPATHY 
 
Introduction 
 The complement system is an important biological cascade involved in the innate 
immune  system’s  defense  against  foreign  infiltrates.  Although  thought  to  exclusively  
serve as a microbial antagonist in the brain, there is now convincing evidence for the 
complement  system’s  role  in  a  swath  of  neurobiological  functions including gross brain 
development, synaptic turnover and network refinement, neurotrophic capabilities and 
opsonization and clearance of misfolded proteins. Once activated, the potency and ability 
for robust amplification of complement effector molecules require that this pathway 
function under strict regulation in order to keep homeostasis. This becomes even more 
important in the brain, which has a high degree of spatial and functional specificity and 
operates at a very narrow set of optimal conditions, such that any over-activation of an 
inflammatory pathway will result in permanent loss of neurons. Thus the brain is 
equipped with several complement inhibitors [reviewed by (Zipfel and Skerka 2009)].  
 Our lab has recently become interested in the type-I transmembrane glycoprotein, 
complement receptor 1 (CR1; CD35) (Figure 11). CR1 is a member of the family of 
regulators of complement activation (RCA), which is located on the long arm of 
chromosome 1 at band 32 (1q32). In fact, each complement regulator located at this 
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position (CD46, CD55, CR2 and factor H) consists of repeating, highly conserved 
domains known as short consensus repeats (SCRs; complement control repeats or sushi 
domains). CR1 consists of up to 44 SCRs in it longest allelic variant. CR1 has 4 isoforms, 
each differing by ~30 kDa: CR1-S (250 kDa), which has a frequency of ~15% with the 
most common isoform, CR1-F (220 kDa), having a frequency of ~83%. Two more 
isoforms exist, CR1-F’  (190  kDa)  and  CR1-D (280 kDa), but at frequency of 1% or less, 
respectively (Wong and Farrell 1991). SCRs make up larger units known as long 
homologous repeats (LHRs), which consist of seven SCRs; the first three SCRs making 
up the C3b/C4b binding site (Krych-Goldberg and Atkinson 2001). The number LHRs 
(one is approximately 30 kDa) determine which isoform is present; CR1-F contains four 
LHRs and CR1-S contains five. It is thought that the CR1-S isoform evolved from a copy 
number variation in a long consensus repeat (LCR), which code for the LHR units 
(Wong, Kennedy et al. 1986). 
One of its main functions (apart from immune adherence, decay-accelerating 
activity for C3 and C5 convertases and phagocytosis) is its ability to bind C3b, mediating 
its cleavage and inhibition in the presence of factor I (Krych-Goldberg and Atkinson 
2001). This particular function seems relevant to our findings of increased C3b in our 
CAA cases. We found that 75% of cases with CAA in our cohort carried a SNP within 
the CR1 gene (rs6656401), which has recently been reported to be associated with high 
plaque volume in AD patients (Chibnik, Shulman et al. 2011) and increased risk for CAA 
and hemorrhage (Biffi, Shulman et al. 2012). Although it is currently unclear how this 
intronic SNP affects CR1 function, based on our observations, we posit that it somehow 
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alters CR1-mediated cleavage of C3b into its inactivated forms iC3b and C3dg, thus 
resulting  in  increased  activated  C3b  levels  and  decreased  phagocytosis  of  Aβ  in  CAA. 
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Figure 12. Protein structure of the four isoforms of CR1. Each isoform differs by ~30 
kDa, which is equal to one LHR. The first three SCRs make up the C3b/C4b binding sites 
(red). Each LHR, except LHR D, has binding sites for C3b/C4b. LHR D has a binding 
region for C1q and mannose-binding lectin. Number of amino acid residues in each 
region is represented at the bottom of the CR1 protein structure. SCR = short consensus 
repeat; LHR = long homologous repeat; CR1 = Complement Receptor 1; TM = 
Transmembrane domain; SP = Signal peptide; C = C terminus; N = N terminus. 
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Due to the limited availability of data on the role of CR1 haplotypes on CR1 
protein function, we chose to analyze human post mortem tissue with known rs6656401 
genotype for CR1 levels and localization.  
 
Materials and Methods 
Human postmortem tissue  
Post  mortem  tissue  was  obtained  from  the  Alzheimer’s  Disease  Research Center 
Brain Bank at the University of California, Los Angeles. All patients or their surrogates 
consented to participate in research protocols prior to tissue donation, and the study was 
approved by the Institutional Review Board of Loma Linda University Medical Center 
(approval #54174). Both frozen tissue specimens and fixed tissues were available for 
study. Neuropathologic examination at the time of autopsy included Braak and Braak 
staging of AD and Vonsattel grading of CAA pathology (6, 12). CAA staging of CAA 
severity is as follows: stage 1- β-amyloid deposition limited to the basement membrane 
of arterioles and primarily involving leptomeningeal vessels; stage 2- β-amyloid 
deposited between vascular smooth muscle cells and pathology extends to penetrating 
arterioles and stage 3- β-amyloid largely replaces vascular smooth muscle in arterioles. 
Specimens were graded based on the majority of vessels displaying the respective 
Vonsattel stage. Microaneurysms and microhemorrhages often occur with Vonsattel stage 
3 CAA.  
 
Immunohistochemistry 
 Paraffin-embedded, formalin fixed sections of temporal lobe tissue were 
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deparaffinized in two exchanges of xylene and rehydrated in serial exchanges of ethanol. 
Antigen retrieval was performed by heating sections in a microwave on high power (3x at 
90 seconds each) in a 10 mM citrate buffer. The sections were then treated with 3% 
hydrogen peroxide in PBS to block endogenous peroxidase activity, solubilized in 0.25% 
Tween-20 in PBS and then incubated with a blocking solution of 3% bovine serum 
albumin (BSA) in PBS-0.1% Tween-20, and incubated with the primary antibody of 
choice overnight at 4°C. After washing with PBS and blocking, sections were incubated 
in ABC reagent (Vector Laboratories) for one hour and then incubated with biotin-
conjugated secondary antibody for 2 h, washed in additional exchanges of PBS and 
treated with diaminobenzidine/hydrogen peroxide (DAB) for 10 min (Vector 
Laboratories), followed by hematoxylin as a counterstain. They were then rinsed for 3 
min in PBS, dehydrated through serial alcohols, cleared in xylene and coverslipped with 
mounting resin (Permount, Fisher). The antibody used included anti-CR1 (H-300 rabbit 
polyclonal, 1:50; Santa Cruz, CA), which recognizes a C-terminus epitope.  
 
Results and Discussion 
In order to determine how the rs6656401 SNP may affect the CR1 protein, we 
started with CR1 IHC on human post mortem tissue from the superior temporal gyrus 
classified as AD without CAA, AD with CAA and age-matched, neuropathological 
controls, all of which included haplotype analysis (Figure 13). CAA samples were further 
grouped into homozygotes (n=3; mild and moderate CAA) and heterozygotes (n=3; all 
mild CAA) at rs6656401. Control samples with A/G haplotype showed confluent CR1 
staining throughout the neuron soma and into the axon in a distribution consistent with 
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plasma membrane. Control vessels additionally showed robust CR1 staining within the 
smooth muscle layer. These observations clearly explain the decreased levels of C3b in 
the parenchyma of control subjects (Figure 4). AD-only neurons with the A/G haplotype 
lacked the same staining as controls, which seemed to localize only in the soma. This 
could be due to the particular tissue slice, but because this distribution occurred in every 
neuron within the samples surveyed, this probably represents a real observation. AD 
cortical arterioles showed similarly robust tunica media staining compared to controls. 
Again, this observations explains the intermediate levels of C3b in AD-only subjects. 
AD/CAA neurons harboring the A/A risk haplotype showed similar intensity of staining 
as control A/G neurons, but CR1 localized to vesicular structures within the soma and 
into the axon hillock. Additionally, CAA A/A vessels lacked CR1 staining within the 
smooth  muscle  layer,  which  could  be  due  to  a  lack  of  smooth  muscle  cells  from  Aβ  
deposition. Further analysis will include A/A haplotypes in the mild CAA range. The 
localization of CR1 in neuronal vesicular structures suggests it cannot gain access to and 
inhibit extracellular C3b, which explains the significantly high levels of C3b in CAA 
subjects. On the other hand, CAA vessels with the A/G haplotype, although not as intense 
as controls or AD-only vessels, showed similar staining within the tunica media. CAA 
A/G neurons demonstrated a mix between control and AD-only CR1 staining. Neurons 
with the A/G haplotype showed qualitatively reduced levels of CR1 and consisted of 
diffuse somal and axonal CR1 staining, with some evidence of vesicular structures. All 
CAA subjects heterozygous at rs6656401 had only mild CAA pathology, which could 
tentatively explain the trending decrease in C3b levels. Separation of CAA patients into 
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heterozygotes and homozygotes will be necessary to specifically confirm the CR1 
haplotype effect on C3b levels.  
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Figure 13. CR1 histology in the brain parenchyma and cerebral vasculature. Control 
neurons show robust CR1 staining in the soma and into the axon, probably on the plasma 
membrane. AD neurons seem to lack the robust staining seen in controls, but instead 
show low levels of CR1 on the plasma membrane and in vesicular structures. In CAA 
patients with the rs6656401 risk SNP (A/A), neurons show CR1 staining in endosomal 
structures within the soma and axon hillock—possibly lysosomes. These neurons also 
lack the diffuse membrane staining demonstrated in controls. CAA heterozygote cases 
(A/G) demonstrate reduced intensity of staining and show CR1 localization to endosomal 
structures, with some membrane staining. Control and AD-only vessels contain CR1 
staining within the smooth muscle media of cortical arterioles, while CAA vessels with 
the risk SNP lack such staining. Heterozygotes show CR1 staining, but at qualitatively 
reduced levels. Photomicrographs of parenchyma = 1000x; vessels = 400x. 
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Besides the small sample size for this histopathological study, a major limitation 
to these findings is the lack of cases with the G/G haplotype in each group. Acquiring this 
group of specimens will be necessary to confirm the present findings that the risk A/A 
haplotype alters the cellular localization of CR1. If having at least one A allele (A/G or 
A/A haplotype) confers significant risk, as suggested by Zhang and colleagues (Zhang, 
Yu et al. 2010), then might the control and AD-only subjects in this cohort have 
progressed to a CAA phenotype should they have lived longer? This question will need to 
be addressed in a longitudinal follow up study with patients harboring all three 
genotypes. Biffi and colleagues showed that heterozygotes for the rs6656401 SNP had an 
intermediate risk for CAA-related hemorrhage compared to A/A and G/G homozygotes 
(Biffi, Shulman et al. 2012), so it seems likely that an intermediate phenotype exists.  
This work is the first to localize the CR1 protein in the context of the rs6656401 
SNP. Because this observation is preliminary, caution must be taken to extrapolate to 
concrete disease mechanisms. The genotyping data for rs6656401 and the difference in 
localization,  however,  lend  credence  for  further  study  of  CR1’s  role  in  CAA  
pathophysiology.   
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CHAPTER FOUR 
 
CONCLUSIONS 
 
 
Discussion 
 
The purpose of this dissertation was to determine a possible mechanism that could 
explain vascular fragility and subsequent increased risk of ICH in CAA patients and if 
this  prospective  mechanism  also  contributes  to  Aβ  deposition  on  vascular  elements.  We  
found that late complement activation in the form of the membrane attack complex, a 
known  cytolytic  entity,  localizes  on  cortical  arterioles  affected  with  Aβ  aggregation.  
Additionally, such complement activation is not counteracted by an increase in the 
endogenous MAC inhibitor CD59 on the same vessels.  
Interestingly, the expression of MAC on CAA-affected vasculature may stem 
from initiation of the cascade in the parenchyma by microglia. In the control brain, 
without  vasculopathy,  clearance  of  Aβ  occurs  via a2M or apoE complexes, which can be 
picked up by LRP-1 on vascular smooth muscle cells and transcytosed into peripheral 
circulation (Zlokovic, Deane et al. 2010). However, in the AD and CAA brain, LRP-1 is 
decreased on VSMCs (Donahue, Flaherty et al. 2006, Bell, Deane et al. 2009). 
Additionally, we found that a2M was unchanged in AD-only patients compared to 
controls, but significantly decreased in AD patients with CAA compared to those without 
CAA  and  controls.  On  the  other  hand,  C3b,  an  opsonin  capable  of  binding  Aβ,  was  
significantly increased in AD/CAA patients compared to controls. This a significant point 
of interest as a2M and C3 are evolutionarily related proteins with nearly identical 
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structure, which share some similar functions (Sottrup-Jensen, Stepanik et al. 1985, Doan 
and Gettins 2007). a2M and C3 each comprise eight macroglobulin (MG) domains, of 
which the eighth constitutes the receptor binding domain with affinity for LRP-1 and 
CR1  or  CR3,  respectively.  A  “bait”  region  lies  at  MG6,  which  acts  to  attract  proteases  
destined to be inhibited by a2M or when cleaved on C3, becomes the C3a anaphylotoxin. 
Upon cleavage of the bait region, the thioester domain (TED) becomes exposed and can 
subsequently form a trap for either a protease, in the case of a2M, or foreign antigen, in 
the  case  of  C3b.  In  both  cases,  Aβ  is  attacked  by  the  TED  and  bound  either  through  an  
ester or amide bond (Dodds and Law 1998). Our results suggest a compensatory 
mechanism facilitated by increased C3 expression in order to relieve the brain milieu of 
increased  Aβ  aggregation  due  to  loss  of  clearance  function  provided  by  LRP-1 and a2M.  
At  this  point  it  is  important  to  take  into  account  a  patient’s  genotype.  In  2009,  
Lambert and colleagues demonstrated in a GWA study a single nucleotide polymorphism 
(SNP) at the CR1 gene, rs6656401, to be significantly associated with late onset AD, 
specifically with an odds ratio of 1.22 (P =3.1x10-10) for the AA haplotype compared to 
the GG haplotype (Lambert, Heath et al. 2009). Since then, other studies have 
corroborated these results finding similar risk associations with the AA haplotype of the 
rs6656401 SNP (Zhang, Yu et al. 2010, Chibnik, Shulman et al. 2011). An even more 
recent analysis of SNP data extended these findings and found increased risk for both AD 
and CAA and suggested the CR1 rs6656401 SNP acts independently on both phenotypes 
(Biffi, Shulman et al. 2012). Subjects carrying the AA risk haplotype had a significantly 
increased risk of CAA severity and CAA-related hemorrhage compared to controls and 
hypertension-related ICH (Biffi, Shulman et al. 2012). Our group found that 75% of the 
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subjects with CAA were homozygous for the A risk allele at rs6656401, whereas control 
patients were heterozygous A/G at this position and only one of four AD-only patients 
was homozygous. An interesting association with this genetic finding is the significantly 
increased levels of C3b in the occipital cortex in AD with CAA patients. We suggest the 
CR1 SNP at rs6656401 could result in a CR1 protein product that ineffectively inhibits 
generation of C3b. In light of the similarities between a2M and C3 and the hypothesis 
that decreased a2M and LRP-1 may lead to a compensatory increase in C3 expression, 
such a dysfunction in the regulation of C3 and C3b may explain the enhanced 
complement activation and amplification towards the distal end of the pathway to 
increased MAC deposition on neurons and on the cerebrovasculature.  
This is not to say that dysregulation of complement and the inappropriate 
trafficking  Aβ  by  microglia  are  the  proximal causes of AD with CAA. Although in the 
most pure cases this may be so, each patient manifesting cognitive decline of the AD type 
may harbor multiple risk factors. The CR1 haplotype described above may simply modify 
the AD phenotype to include vascular  Aβ  pathology  with  excess  complement,  which  
undoubtedly does cause the small microbleeds that are very apparent in CAA subjects 
(Soontornniyomkij, Lynch et al. 2010).  The  ApoE  ε4  allele  (Greenberg, Briggs et al. 
1996) and a polymorphism in the oxidized LDL receptor 1 gene (Shi, Tian et al. 2006) 
also increase the risk of amyloid angiopathy. Simply put, the etiology of AD is 
heterogeneous and thus this should be taken into account in developing therapeutics in 
order to effectively treat the insulting factor. For example, our work will be important 
clinically. Knowledge of the CR1 SNP in a particular patient should facilitate their 
removal from clinical trials using therapies that might exacerbate the CAA phenotype 
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such  as  Aβ  immunotherapy  (as  described  in  Chapter  two;;  see  Discussion).  Additionally,  
because of the inherent weakness in the vascular wall as a function of MAC activation, it 
would not be prudent to give patients harboring the rs6656401 SNP anticoagulant 
therapy, which could manifest cognition altering microbleeds or fatal hemorrhages. 
 
Future Directions 
It was recently posited that risk for AD could be due to a copy number variation 
which encodes one extra copy of the low-copy repeat (LCR) in the CR1 gene resulting in 
an extra C3b binding site on the CR1 protein (Brouwers, Van Cauwenberghe et al. 2012). 
The premise being that the extra binding site allows for more inhibition of C3b 
generation, which would fit the animal data presented by Maier et al. and Wyss-Coray et 
al. that decreased C3b exacerbates the AD phenotype. Work done by our lab, however, 
suggests this may not be the case in humans as we have found increased levels of C3b in 
patients with CAA and the associated CR1 SNP. Since they do not state the status of 
vascular  Aβ,  perhaps  the  association  signal  they  are  reporting is due to the mechanism we 
are proposing—that  because  CD11b  and  CR1  are  synergistic  in  their  ability  for  Aβ  
uptake,  increased  binding  sites  on  CR1  would  allow  more  C3b  and  Aβ  to  be  bound  to  
CD11b and delivered to the blood vessel wall resulting in vascular fragility. Because of 
this important implication, it will be necessary in the future to include the CAA 
phenotype in the demographics of each cohort.  
Further questions remain. For example, because 75% of our cohort of patients 
with CAA were homozygous for the A allele, it is so far difficult to conclude that the 
resulting phenotype exists in, albeit rare, CAA patients with the G/G haplotype. Do such 
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cases still manifest robust vascular MAC staining? Do CAA carriers of both G alleles 
have normal clearance of  Aβ  via  C3b  despite  decreased  levels  of  LRP-1 and a2M? This 
question could be answered in an a2M or LRP-1 knock out mouse model, which only 
manifests parenchymal plaque pathology. We hypothesize that loss of the LRP-1/a2M 
pathway will push  Aβ  clearance  towards a CD11b/C3b pathway  and  vascular  Aβ  
deposition.  
Our current analysis on the CR1 protein in pathologically characterized AD 
patients with CAA, which will include the CR1 genotype at rs6656401, will further 
delineate  the  CR1  protein’s  role  in  AD  and CAA etiology. Ongoing work is separating 
the CAA group into homozygotes and heterozygotes to study the levels of CR1. 
Additionally, cell culture studies are being performed on SH-SY5Y neuroblastoma cells 
to delineate mechanisms of CR1 dysfunction. Using site-specific mutagenesis to manifest 
the A allele, the effect of the CR1 variation on CR1 protein levels, localization and 
function can be studied in a model mimicking the disease environment. This can be 
accomplished by introducing soluble and fibrillar Aβ  or oxysterols (27 OHC), which 
have been shown to alter levels of proteins associated with neurodegeneration (Rantham 
Prabhakara, Feist et al. 2008). Additionally, the rs6656401 SNP is not in a protein coding 
region of the CR1 gene. Instead, the SNP lies between exon 4 and exon 5. Intronic SNPs 
at CR1 have been shown to alter CR1 protein density on the plasma membrane (Liu and 
Niu 2009). Such an intronic variation could explain our findings both in AD and CAA 
patients presented in figure 13 above. For example, in heterozygote AD and CAA 
subjects, we found CR1 in the soma, but apparently decreased. Under a non-specific, 
multi-hit hypothesis, the A/G allele may not affect the CR1 protein density or localization 
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directly unless there is some other insult, such as cellular stress manifesting as 
inflammation or oxidative injury, which are commonly found in AD brains. In patients 
homozygous for the A allele, the intronic SNP probably alters the localization directly, 
which is why we found CR1 localized to intracellular vesicular structures. These 
observations need to be tested in the in vitro model suggested above to confirm this 
hypothesis. In aggregate, this human and in vitro work will hopefully yield a clinically 
relevant genetic biomarker and a better understanding of CR1 variation on AD and CAA 
etiology.  
In addition, knowledge of a complement-mediated attack on cerebral blood 
vessels may also provide clinicians with a therapeutic avenue. It has been reported in 
several case studies that the inflammatory subtype of CAA can be treated successfully 
with steroids (Scolding, Joseph et al. 2005, Chung, O et al. 2009, Kloppenborg, Richard 
et al. 2010, Chung, Anderson et al. 2011, Kimura, Sakurai et al. 2013). These case reports 
provide a proof-of-concept model of blocking vascular inflammation as a viable therapy 
for patients with CAA. Although steroid administration can block classical complement 
activation (Muraki, Hamano et al. 2006), it is non-specific and can manifest deleterious 
side-effects. Therefore, more specific, targeted approaches are necessary. 
We are currently developing a nanoparticle-based therapy based on our findings. 
Briefly, chitosan nanoparticles have been packaged with a cDNA plasmid and are coated 
with the M31 anti-vascular  Aβ  antibody.  This  antibody,  developed  by  Charles  Glabe  at  
UC  Irvine,  has  been  selected  for  its  remarkable  ability  to  specifically  target  Aβ  deposited 
within the smooth muscle layer of cerebral arteries, while sparing parenchymal plaques 
(Kayed, Canto et al. 2010). The goal of this preclinical work is to block MAC activation 
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on  vessels  affected  by  Aβ  deposition,  first  in  an  in vitro microfluidic model and then in 
vivo. This therapy is currently under development in order to save the microvasculature in 
complement-mediated vasculopathies, as seen in AD with CAA.  
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APPENDIX 
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Supplementary Figure 1. Negative  controls  for  CD11b  and  Aβ  confocal  images.  Images  
were taken at 400x magnification and followed a similar protocol, and were incubated in 
FITC and Texas Red conjugated secondary antibodies without primary antibody 
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Supplementary Figure 2. Immunoprecipitation was performed on all target proteins 
from Fig. 3. Western blots for CD11b were done on precipitates of a C3b, b ApoE4, c 
Aβ40/42  to  confirm  findings  in  Fig.  6. 
 
  
 121 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3. Negative control on an AD/CAA case for C5b-9 (MAC) 
staining on fixed occipital lobe sections. Images were taken at 200x magnification and 
were prepared using a similar protocol and were incubated in Dylight 550 conjugated 
secondary antibody without primary antibody. A negative control image for Thioflavin S 
was  taken  without  staining  on  the  green  channel.  Scale  bar  =  200  μm. 
 
 
 
 
 
 
 
 
 
 
